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Cancer stem cells (CSCs) are proposed to be responsible for breast cancer heterogeneity, 
chemotherapeutic treatment failure, metastatic spread and disease recurrence. The precise 
identification of the molecular bases that govern the induction and maintenance of CSCs and 
their aggressive phenotypes is of utmost importance, since it may provide the rational to develop 
effective therapeutic strategies. In particular there is a considerable effort in finding common 
pathways, mutations or histological features that might be targeted for therapy, overcoming 
breast cancer heterogeneity.  
Here we now demonstrate that CSC self-renewal, chemoresistance, tumour growth and 
metastases formation capabilities’ are under direct control of Pin1’s enzymatic activity on the 
Notch signalling pathway. In particular Pin1 protects the nuclear activated forms of Notch1 and 
Notch4 (N1/4-ICD) from their E3-ubiquitin-ligase Fbxw7α, thereby boosting their protein levels 
and transcriptional activity. Fbxw7α acts as a potent inhibitor of CSCs maintenance by 
promoting protein degradation of N1- and N4-ICD, and, as a consequence, this ubiquitin-ligase 
strongly decreased tumour growth and metastases dissemination in vivo. Interestingly, 
concomitant over-expression of Pin1 almost completely recovered all these aggressive breast 
cancer traits.  
In tissues from breast cancer patients, we observed Notch signalling over-activation despite 
presence of the negative regulator Fbxw7α, which relied on high Pin1 protein levels. Notably, 
activation of the Notch-Pin1 axis correlated with poor prognosis in these patients. 
As a consequence of our findings, suppression of Pin1 holds promise in reverting aggressive 
phenotypes in breast cancer through shrinkage of CSCs number and a concomitant gain in 












3.1. Breast cancer: a heterogeneous disease 
 
Breast cancer is the most common cause of cancer death among women (522 000 deaths in 
2012) and the most frequently diagnosed tumour type in 140 out of 184 countries worldwide 
(Bray et al., 2013). Despite death rates have dropped by 34% from 1990 to 2013 in the United 
States due to an earlier diagnosis, better histopathological classifications and more specific 
pharmacological treatments (Desantis et al., 2014; Weigelt et al., 2005), a significant percentage 
of these patients still die. This is partly due to lifestyle changes that cause increased incidence, 
but also because of treatment failures and the inability to hinder dissemination and growth of 
metastases (Polyak, 2011; Steeg and Theodorescu, 2008). From a clinical point of view, the main 
goal of treatment is eradication of the tumour and prevention of metastatic growth. Even though 
therapeutic strategies have evolved, the three main pillars on which clinicians still rely are 
represented by surgery, radio- and chemotherapy. Unfortunately, despite increasing advances, 
when a tumour enters the metastatic phase, the probability of a cure is extremely reduced (Longo 
et al., 2011). The main cause of the mild improvement of the clinical management of malignant 
breast cancers resides in their intrinsic inter-tumoural and intra-tumoural heterogeneity. Breast 
cancer is not a single disease but a collection of breast diseases, with different genetic variations, 
gene expression profiles, histopathological features, pharmacological response and clinical 
outcomes (Kreso and Dick, 2014; Stingl and , 2007; Vargo-Gogola and Rosen, 2007). 
The possibility to associate mutations or cancer properties to a specific cell type or stage of 
differentiation could contribute to better classify similar tumours, and to propose tumour type 
specific interventions. Indeed, breast cancer heterogeneity suggests the hypothesis that breast 
cancers can initiate in different cell types, either breast epithelial stem cells or their progeny. 
However, the cellular hierarchy of the mammary gland and the cell of origin of different classes 
of breast tumours are still open questions that await elucidation. 
 
3.1.1 Classification of breast cancer subtypes: advances and pitfalls 
Gene expression profiles and histological staging offered the opportunity to classify human 
breast cancers in 5 different major subtypes: normal-like, luminal A, luminal B, HER2+, basal-
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like and claudin-low (Eroles et al., 2012; Perou et al., 2000; Sorlie et al., 2001; Sorlie et al., 
2003; Sotiriou et al., 2003). This type of classification is useful not only for assessment of 
prognosis but also for the best fitting therapeutic regime.  
The luminal A breast cancer is the most common subtype, decteted in almost 50% of breast 
cancer patients. They are characterized by expression of estrogen receptor (ER), its target genes 
and progesterone receptor (PR) in the luminal epithelium, low rate of proliferation, low 
histological grade, good prognosis and they respond to ER modulator drugs. 
The luminal B subtype is less present than the A type but these tumours are more aggressive, 
with high proliferation rate, worse prognosis and they do not have a specific treatment regime as 
not always responding to ER modulators. 
The HER2 positive subtype represents al least 15-20% of all breast cancers, and they are 
characterized by a high expression of the HER2 gene or amplification of HER2 gene, or up-
regulation of modulators of its pathway characterizes them. These tumours display high 
proliferation rate, high histological grade and worse prognosis. From a clinical point of view the 
discovery of anti-HER2 molecules strongly changed the median survival of these patients, 
reducing the metastases formation but also curbing primary tumours.  
The Basal-like subtype represents 10-20% of all breast carcinomas that expresses genes usually 
present in normal breast myoepithelial cells. This subtype of cancer is characterized by large 
tumour size, high histological grade, high frequency of lymph node affection and poor overall 
survival. They are characterized by lack of expression of the 3 key molecular targets present in 
the great proportion of breast tumours, namely ER, PR and HER2. For this reason, a large 
percentage of Basal-like breast tumours are also called Triple Negative breast cancers, or TNBC.  
Moreover, since there is no specific molecular target to date, the therapeutic regime for these 
patients still relies on chemotherapy.  
The Claudin-low subtype represents 12-15% of breast tumours and it is defined by low 
expression of genes involved in the regulation of tight junctions, inter-cellular adhesion (claudin-
3, -4, -7) and epithelial markers (E-Cadherin). They are similar to basal-like tumours, but they 
differ by the fact that the claudin-low subtype is strongly infiltrated by immune system cells and 
moreover they are characterized by overexpressions of genes linked to mesenchymal 
differentiation and epithelial-to-mesenchymal transition (EMT).  
 
This subtype classification is not only relevant to define the most fitting therapeutic approach, 
but it is also useful to predict the clinical outcome and to provide, at times, possible explanation 
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to the failure of the pharmacological regime. In addition, the recent discovery of other breast 
cancer subtypes (Eroles et al., 2012; Sims et al., 2007), as a consequence of more comprehensive 
genomic and transcriptomic analyses, unveiled that a definitive classification is still far to come. 
However, such classifications are inherently problematic, since they are based on molecular 
analyses on a heterogeneous population, and they don’t take into account that, in a tumour cell 
population, there is a collection of various statuses of differentiation, cellular commitment, and 
mutational landscapes (Gerlinger et al., 2012). Moreover, the heterogeneity in breast cancer is 
even more complex. For example a HER2 breast cancer subtype is classified on the basis of the 
percentage of cells in the tumour mass display amplification of its gene –or up-regulation of its 
pathway– that exceeds a particular cut-off. Thus, even if a tumour is classified as HER2, not all 
tumour cells exhibit high levels of this receptor (Wolff et al., 2013), leading to the existence of 
genetic and epigenetic intra-tumour variability (Marusyk and Polyak, 2010; Polyak, 2011). Thus, 
even though personalized medicine using targeted agents is considered a more promising way to 
target individual tumours than simple chemio- or radiotherapy, intra-tumour heterogeneity 
represents an important hurdle to the achievement of a complete patients’ response.  
Different approaches in cancer research are converging to provide more insights into the 
underlying mechanisms of tumour heterogeneity and uncovering how these are linked to therapy 
resistance, tumour progression, and recurrence. In this regard, therapies aimed at targeting 
“cancer stem cells” have gained much attention (Figure 1) (Kreso and Dick, 2014). 
 
Figure 1. Stemness as a guiding principle that governs therapeutic response 
Three fields in biology—cancer genetics, epigenetics, and microenvironment— are coming together to provide 
increasing clarity to the processes that determine stemness and in turn influence clinical outcome. These three 
factors can influence stemness simultaneously, but they can also act independently over time. Through evolutionary 
time, different forces can impact a cell’s stemness properties and thereby shape tumor progression and therapeutic 
response (Kreso and Dick, 2014). 
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It is increasingly acknowledged that a subpopulation of cancer cells, termed cancer stem cells 
(CSCs) play a major role in cancer growth, metastasis formation and chemoresistance in breast 
cancer (Dean et al, 2005; Stingl & Caldas, 2007; Visvader & Lindeman, 2012). Like their 
normal counterpart, CSCs are able to self-renew and maintain a reservoir of cancer-initiating 
cells, which may produce a more differentiated progeny of cells and contribute to intra-tumour 
heterogeneity (Stingl & Caldas, 2007). Current breast cancer research aims at better classifying 
breast cancer subtypes and defining the molecular circuitries of subtype-specific CSCs, trying to 
find common pathways, mutations or histological features that might be targeted for therapy, 
overcoming breast cancer heterogeneity. Indeed, there is emerging evidence, that despite the 
multiplicity of molecular signatures, receptors expression, histopathological features and intra-
tumour heterogeneity, a common characteristic that could underlie these differences, are the 
CSCs (Kreso and Dick, 2014; Magee et al., 2012; Pece et al., 2010; Stingl and Caldas, 2007; 
Visvader and Lindeman, 2012) 
 
3.1.2. Normal stem cells of the mammary gland 
The mammary gland is a tubulo-alveolar gland, composed by three lineages of epithelial cells, 
i.e. luminal, myoepithelial and alveolar epithelial cells that derive from luminal progenitors and 
are differentiated for synthesizing milk proteins. The mammary gland undergoes a sequence of 
dynamic changes throughout the female life cycle (Gjorevski and Nelson, 2011), and the 
capacity of the mammary gland epithelium to expand and remodel during puberty and repeated 
cycles of pregnancy is highly suggestive of the existence of resident mammary gland stem cells 
(SCs) in the adult (Visvader, 2009).  
The first evidence of the existence of mammary stem cells derived from experiments in which a 
transplantation of different dissected parts of the mammary gland into the fat pad of syngenic 
rodents, gave rise to fully developed and functional mammary glands (Hoshino, 1964). Other 
studies carried out with the purpose to identify a stem cell population able to regenerate the 
mammary gland (Gudjonsson et al., 2002; Rudland et al., 1997), but the isolation and 
characterisation of a true stem cell population from both humans and mice, has been obtained 
only few years later, using in vitro and in vivo reconstitution transplantation experiments (Dontu 
et al., 2003a; Dontu et al., 2003b; Stingl et al., 1998; Stingl et al., 2001; Stingl et al., 2006). 
Afterwards, the generation of the different mammary epithelial cells by resident mammary stem 
cells was demonstrated by two different groups through lineage-tracing experiments in mice, as 
depicted in the scheme of Figure 2 (Rios et al., 2014; Van Keymeulen et al., 2011; Visvader and 




Figure 2. Model of the epithelial differentiation hierarchy in the mammary gland 
There is recent evidence for a heterogeneous compartment of stem cells, in which the stem cell at the apex is 
multipotent and likely has higher self‐renewing capacity than the unipotent stem cells (myoepithelial‐stem cell, 
Myo‐SC; luminal‐stem cell, Lum‐SC) and the ‘shorter‐term’ mammary repopulating cell that emerges in pregnancy 
(Preg‐SC). Alternatively, there may be one true stem cell and a hierarchy of descendant progenitor cells (indicated 
by overlap between the stem and progenitor cell compartments) that include long‐ and short‐lived lineage‐restricted 
progenitors (Visvader and Lindeman, 2011). 
 
 
Adult stem stem cells are defined as undifferentiated and multipotent or bi/unipotent cells that 
have the potential to differentiate and generate the specialized end cells of that tissue. Moreover 
they are able to self-renew, so to maintain in this way the stem cells’ compartment for many 
passages, and to generate some committed progenitors with tissue maintaining potential. This 
ability is a consequence of their peculiar way of cell division. Indeed they are able to divide 
giving rise to one stem cell, identical to the initial stem cell, and a daughter committed 
progenitor cell, which undergoes a differentiation process. This type of division is called 
asymmetric. By contrast, in specific conditions, stem cells are able to divide also symmetrically 
and generate two stem cells, without the differentiated one, expanding in such way the stem cell 
pool (Liu et al., 2005; Stingl and Caldas, 2007).  
Seminal work performed by Shackleton and Stingl has provided proper means to isolate and 
characterize a stem cell population capable of reconstituting a functional mammary gland in 
mice, called mammary repopulating units (MRUs) (Shackleton et al., 2006; Stingl et al., 2006). 
MRU cells are purified from the mammary gland after digestion and sorted by both excluding 
cells expressing hematopoietic and endothelial markers and including the expression of CD24, 
α6-integrin (CD49f), Sca-1 and β1-integrin (CD29). In particular, cells with a 
CD24med/CD49fhigh profile characterize the MRU population and it is present in a proportion of 1 
MRU out of 1400 total cells in mice.  
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Moreover, by using an in vitro colony assay, other groups have demonstrated that a small 
subpopulation of mammary gland stem cells (MaSC) is able to give rise to luminal and 
myoepithelial lineages, suggesting the existence of bipotent stem cells (Dontu et al., 2003; Guo 
et al., 2012). Another in vitro experiment, that is now a widely used as a surrogate stem cell 
assay, is based on the ability of cells to generate clonal mammospheres in non-adherent, serum-
free conditions and it evaluates the stem cells’ content in a breast cell line or tissue. Notably, 
these mammospheres are enriched in multi-lineage progenitors and display a transcriptional 
profile enriched in stemness factors and pathways (Dontu et al., 2003). 
The ability to prospectively isolate and analyze the stem cell population of the mammary gland 
gives the opportunity to identify molecular signatures and factors required for their own 
maintenance. In fact, thanks to these methods, many groups had dissected the molecular bases of 
stem cells from both mouse and human breast tissues delineating the main factors involved in 
stemness (Ben-Porath et al., 2008; Dontu et al., 2003; Pece et al., 2010; Raouf et al., 2008; Spike 
et al., 2012)  
In summary, a huge number of data allowed identifying a stem cell population that is able to 
generate, in vitro, mammospheres and colonies composed of both lineages and, more 
importantly, an entire functional mammary gland in vivo. Notably the isolation and 
characterisation of human mammary stem cells lacks a real in vivo validation, but the in vitro 
assays are well established and reliable.  
 
3.1.3 Breast cancer stem cells 
Breast cancer stem cell (CSCs) research is one of the most investigated fields in breast cancer 
research in the last years. Like normal stem cells that are able to regenerate an organ, also CSCs 
are considered to be responsible for re-generation of the tumour, as demonstrated by sequential 
transplantation assays. From a clinical point of view breast CSCs are associated to 
aggressiveness in breast cancer since they are chemoresistant, they have been linked to 
metastases formation and associated to the undifferentiated, poor outcome breast cancer subtypes 
(Stingl and Caldas, 2007; Valent et al., 2012; Visvader and Lindeman, 2012). Interestingly, the 
most aggressive and high-grade breast cancer subtypes display an enriched CSCs population and 
a stem cell-like signature (Ben-Porath et al., 2008; Pece et al., 2010). As a matter of fact, a better 





3.1.3.1 Breast CSCs: origin and history 
There is increasing evidence that normal stem cells might be the targets of transformation during 
tumourigenesis. Tumours are believed to arise through a series of mutations that occur over 
many years. Adult stem cells are slowly dividing, long-lived cells, which by their very nature are 
exposed to damaging agents for long periods. There are two possible theories concerning the 
formation of CSCs. The first, also called the CSC hypothesis, claims that in some cancers CSCs 
have arisen from normal stem cells that, through acquisition of genetic and epigenetic 
modifications, become cancerous and display perturbed self-renewal. Another possibility is that 
terminally differentiated epithelial cells, or restricted transient amplifying progenitors, through 
clonal evolution, acquire tumourigenic features and, through reprogramming or acquisition of 
plasticity, they lose their committed fate and become more stem-like. Although no clear in vivo 
evidence of the CSC origin has been yet found, in favour of the first hypothesis comes the 
observation that normal stem cells and cancer stem cells share several important features (Dontu 
and Wicha, 2005; Liu et al., 2005; Stingl and Caldas, 2007; Visvader and Lindeman, 2012). 
Using different experimental approaches, several investigators proved how only a minority of 
cells in human cancers are capable to self-renew. This has been most convincingly demonstrated 
by examining the ability of subpopulations of tumour cells identified by cell surface markers to 
form tumours when transplanted into immunosuppressed NOD/SCID mice. This approach was 
first successfully used to demonstrate the existence of leukemic stem cells (Dick, 1996) and, 
some years later, also for breast cancer stem cells (Al-Hajj et al., 2003). Using the cell surface 
markers CD44 and CD24, Al-Hajj and colleagues have been able to isolate a putative CSCs 
population since a small number of injected cells was able to generate a tumour in a host mice. 
There is now evidence for the existence of CSCs in many other tumours (Valent et al., 2012; 
Visvader and Lindeman, 2012), thus suggesting that CSCs are present in a wide number of 
cancers and, as a consequence, they could be considered as a hallmark of cancer.  
The identification of pathways that govern CSCs’ maintenance is important to develop targeted 
therapies. The developmental Notch pathway, Bmi-1, Hedgehod and Wnt signalling, p53, c-myc, 
TAZ, ErbB2 and regulators of epithelial-to mesenchymal transition such as Slug, are the main 
regulators of stemness in breast cancer (Mani et al., 2008; Valent et al., 2012). Tumour-specific 
reactivation of some of these pathways or abrogation such as for p53, is able to re-program a 
committed or progenitor cell to a more dedifferentiated cell with stem cell features. Since most 
of these factors are also involved in cancer development it is evident how some genetic or 
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epigenetic mutations, that drive tumourigenesis, are able to promote formation of a stem cell 
population. 
 
3.1.3.2 Breast CSCs isolation and functional characterisation  
Nowadays no clear and unique assay has been validated and demonstrated to isolate breast 
CSCs. A multi-approach experimental detection and analysis of CSCs, indeed will be more 
predictive and reliable (Stingl and Caldas, 2007; Visvader and Lindeman, 2012). The most 
important and well-validated assay is the in vivo transplantation in immunodeficient mice. This 
assay evaluates the most peculiar trait of CSC, which is the ability of these cells to re-generate a 
tumour. For this reason CSC are often called tumour-initiating cells. In particular, while a CSC is 
able to generate a tumour, the differentiated counterpart of the tumour is unable to (Valent et al., 
2012). This assay allows also to compare the CSCs’ content of different tumours: indeed, 
injection of low numbers of cells gives rise to tumours when derived from breast tumour/cell 
lines with a high content of putative CSCs, while the same amount of cells from tumours 
displaying a low CSCs’ content are not able to generate tumours with the same frequency. 
However, despite the reliability of this in vivo assay, there are some limitations: i) being host 
mice immunodeficient the innate and cell-based immune reactions as well as the content of 
cytokines is deranged, hence, depending on the injected cells, tumour development in these mice 
may be either facilitated or suppressed ii) the host mice lack the tumour microenvironment that 
is required as a supportive scaffold for tumours and CSCs, iii) the presence of both stem and 
progenitor cells requires second-generation recipient animals to better distinguish true stem cells 
from early progenitors which have the potential to generate some tumours in the first  but not in 
the second transplanted animal (Valent et al., 2012). 
The isolation of CSCs with specific markers is widely used but also this type of analysis has its 
own limitations. As a fact, no single marker to isolate/identify the CSC has yet been found. The 
first demonstration of the breast CSCs has been made by prospective immunophenotypic cell 
isolation using the surface markers CD44 and CD24. In particular, CSC are enriched in the 
CD44+/CD24low/- population, as demonstrated by generation of tumours in host mice when 
injected in vivo. This immunophenotypic analysis is widely used but CD44 and CD24 cannot be 
considered as universal markers, indeed their usage does not allow to selectively evaluate and 
enrich for CSCs in ER- and triple negative breast cancers, as demonstrated by the fact that CSCs 
were found in both the CD44+/CD24- and CD44+/CD24+ (Meyer et al., 2010). 
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Ginestier and colleagues have discovered another breast CSC marker some years later. In 
particular they unveiled that both breast normal and cancer human mammary epithelial cells with 
increased aldehyde dehydrogenase activity (ALDH1) have stem/progenitor properties. 
Moreover, the ALDH1+ cells isolated from human breast tumours contain the CSCs population 
enabled with the capacity to self-renew and to generate tumours that recapitulate the original 
heterogeneity of the breast cancer from which they derive. Moreover, by performing a double 
flow-cytometry analysis of xenografted tumours with the stem cell markers ALDH1 and 
CD44+/CD24-, they identified only a small overlapping cell fraction, representing 1.2% of the 
entire population. This doubly recognized CSCs population displayed a higher tumourigenic 
capacity with respect to the single populations positive for one of the two markers. Thus, a 
double analysis of the same tumour population is strongly suggested to better define the CSCs 
subpopulation (Ginestier et al., 2007). 
By taking advantage of the knowledge derived from neurospheres, Dontu and her colleagues 
established an in vitro assay called mammosphere assay. Analogously to primary neural cells, 
human mammary epithelial cells form spherical colonies, termed non-adherent mammospheres, 
when cultured in suspension on non-adherent surfaces in the presence of specific growth factors. 
These mammospheres are enriched in cells with functional characteristics of stem/progenitor 
cells. Transcriptional profiling of mammosphere-derived cells demonstrated significant overlap 
with the genetic programs of other stem cells. The use of this culture system facilitates the 
isolation and characterisation of mammary stem cells and it is useful to test their self-renewal 
ability as well as to understand the pathways that govern their self-renewal and differentiation 
(Dontu et al., 2003a). Almost all the research groups that have studied human and mouse stem 
cells from both normal and tumour breast tissues have extensively used this assay. Such assays 
have obvious caveats as factors important to the in vivo growth and self-renewal may not be 
provided by the in vitro conditions. As a result cells may be selected anomalously, or they are 
induced to differentiate or, more importantly, the true stem cells may be not selected. Moreover 
while CSCs have an unlimited proliferative potential, their growth in vitro is limited to some 
weeks/month. Therefore, results from mammosphere assays must be paralleled by in vivo 
evidence (Valent et al., 2012). 
More recently other markers of human normal and breast CSCs have been described. The work 
was based on the intrinsic ability of CSCs to divide with lower frequency than their 
differentiated progeny. PKH-26 is a fluorescent dye that binds to cell membranes and segregates 
in daughter cells after each cell division, hence the intensity of staining inversely correlates with 
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the number of cell divisions. Notably PKH-26high, slowly dividing cells were able to regenerate 
both an entire mammary gland and mammospheres with high efficiency. Transcriptional 
profiling of these cells, derived from human reductive mammoplasty, allowed determining a 
normal breast stem cell specific signature able to predict biological and molecular features of 
breast cancers. Indeed, in high-grade breast cancers the number of PKH26pos cells is increased, 
indicating a higher CSCs content. By contrast, PKH-26neg, highly dividing cells, were unable to 
generate mammary glands and mammospheres and they displayed markers of terminal 
differentiation. Thus, PKH26pos cells are defined as stem cells (Cicalese et al., 2009; Pece et al., 
2010). 
Taken one by one, all the techniques used to isolate and analyze stem cells display some 
weaknesses; a combination of them will be more precise and clinically relevant for a better 
evaluation of the CSCs population. In addition, the in vivo experiments are the most reliable ones 
and may facilitate the future development of methods for interrogating CSCs in patient samples 
for clinical purposes. 
 
 
3.1.3.3 CSCs underlie heterogeneity of human breast cancers 
Breast cancer inter/intra-tumour heterogeneity represents a major problem in defining the fitting 
pharmacological regime for each patient. Indeed, despite classification of breast cancer subtypes 
has a prognostic value and can properly suggest the better therapy for each single patient, 
considerable heterogeneity in response to therapy still exists. As a result, there has been 
considerable effort in the breast cancer research community to identify biomarkers that more 
accurately predict patients outcome (Stingl and Caldas, 2007). For many reasons CSCs are 
suggested as responsible for this heterogeneity, as follows.  
   - Cancer stem cells boost tumour formation and give rise to a progeny with the same 
mutational features. Notwithstanding, CSCs and the more differentiated progeny display 
different phenotypic traits, as demonstrated for example by a different sensitivity to 
chemotherapeutic agents, contributing to intra-tumour heterogeneity. This aspect is even more 
exacerbated if more differentiated cells within a tumour, due to their genomic instability and 
increased proliferation, could acquire other epigenetic or genetic mutations. In this way the 
tumour will display different cell clones concurring to the intra-tumour heterogeneity, as 
depicted in Figure 3 (Stingl and Caldas, 2007; Kreso and Dick, 2014).  
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Figure 3. Unified model of clonal evolution and CSCs 
Upper panel shows that acquisition of favorable mutations can result in clonal expansion of the founder cell. In 
parallel, another cell may gain a different mutation that allows it to form a new subclone. Over time, genetic 
mutations accumulate and subclones evolve in parallel. Lower panel shows that it may be that CSCs are not static 
entities but can evolve over the lifetime of a cancer as genetic changes can influence CSC frequency. Some 
subclones may contain a steep developmental hierarchy (left), where only few self-renewing CSCs exist among a 
large number of non-CSCs. Other subclones (middle) may contain an intermediate hierarchy, where the number of 
CSCs is relatively high but a hierarchy still exists. Some subclones may have the genetic alterations that confer high 
self-renewal potential, where most cells are tumorigenic. In this scenario, applying the CSC concept to such 
homogeneous subclones is not warranted because most cells can self-renew and few non-CSC progeny are 
generated (Kreso and Dick, 2014). 
 
 
   - It has been demonstrated that cancers can even harbour heterogeneous and biologically 
distinct populations of CSCs, as shown for leukaemia, colorectal and skin tumours (Goardon et 
al., 2011; Visvader and Lindeman, 2012). Intriguingly, distinct CSCs within a tumour have also 
the potential to interconvert, as demonstrated in skin squamous cell carcinomas. Since the 
leukaemia model is closely related to that of breast cancer, it is conceivable that also in breast 
cancers different pools of CSCs coexist and are able to interconvert (Visvader and Lindeman, 
2012).  
  - As mentioned above, there is no great overlap between CSCs from the same breast cancer, 
when selected by different markers, suggesting presence of different types of CSCs highlighted 
the presence of genes associated with stemness features and, notably, increased aggressiveness 
and tumour grade can partially be ascribed to a higher CSCs content (Ben-Porath et al., 2008; 
Pece et al., 2010). Hence, these findings imply that increased percentage and heterogeneous 
CSCs may contribute to tumour heterogeneity explaining the different types of breast cancers. 
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3.1.3.4 CSCs are responsible for the failure of chemotherapeutic treatment 
Clinically, chemoresistance is probably the major problem for treatment of breast cancers. Many 
studies have been carried out to better understand the molecular basis of chemoresistance in 
tumours. Collectively, these studies provide evidence that even within a single genetic clone, 
cancer cells are heterogeneous in their ability to survive chemotherapeutic insults, and point out 
both CSCs and tumour heterogeneity as major responsible for the failure of chemotherapeutic 
treatment (Figure 4) (Kreso and Dick, 2014; Dean, 2009; Dean et al., 2005). 
In 1996 Goodell and colleagues, while staining murine bone marrow cells with the vital dye 
Hoechst 33342, discovered a population that contained low -or none- levels of fluorescence 
(Goodell et al., 1996). They called this population “side population” (SP), a “negatively stained” 
pool of cells that displayed hematopoietic stem cells traits since, upon transplantation into 
irradiated mice, they were able to reconstitute the bone marrow. Subsequent studies unveiled the 
presence of SPs in many tissues including brain, breast, lung, heart, pancreas, testes, skin, and 
liver that were enriched in stem cells. This technique leads to the identification of SP also in 
tumours and in particular in breast, lung, and neural tumours. The fact that this SP does not 
retain the dye is due to its intrinsic ability to exclude dyes through specific ABC transporters 
(ABCB1; ABCG2; ABCC1), promiscuous transporters of both hydrophobic and hydrophilic 
compounds such as dyes and drugs. Interestingly the SP in mammary tissues identify a stem cell 
population, suggesting that stem cells could promote efflux of dyes and, more importantly, 
drugs, underling a related chemoresistant properties of these cells. Indeed CSCs expressed high 
levels of these drug efflux pumps and are resistant to chemotherapy (Sarkadi et al., 2006).  
The CSCs chemoresistance goes beyond the presence of ABC transporters. Although it is well 
known that chemoresistance could arise in any cell of a cancer through several mechanisms such 
as mutation, such features are more likely to be already present in CSCs. Indeed, CSCs, like 
normal stem cells, are relatively quiescent, resistant to apoptosis and they possess an efficient 
DNA-repair capacity (Dean et al., 2005).  
It is evident that CSCs are the main responsible for the failure of chemotherapeutic treatment, 
since they already intrinsically possess a plethora of chemoresistance mechanisms. Even worse, 
despite treatment of breast cancer patients with chemotherapy causes an initial shrinkage of the 
tumour mass, a concomitant increase in the percentage of resistant cancer stem cells was 
observed. Notably, in vitro and in vivo experiments with cells obtained from these treated 
tumours demonstrated that these cells eventually regenerated an even more aggressive tumour, 
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phenocopying tumour recurrence after therapy (Figure 4) (Kreso and Dick, 2014; Dean, 2009; 






Figure 4. CSCs within subclones impact response to therapy 
Each clone (depicted by the different colors) contains a mixture of cells that vary with respect to their stemness 
and/or proliferative ability, including dormant or CSCs (depicted by a central dot in the cell). Together these factors 
represent the functional diversity present within single genetic subclones. Chemotherapy can reduce tumor burden 
by eliminating the highly proliferative cells within subclones, while sparing the CSCs; following therapy, these cells 
can seed a new cancer. Thereby, subclonal diversity can be altered with chemotherapy and can allow for the 












3.1.3.5 EMT and metastases are linked to CSC traits 
 
Aggressive and deadly tumours are characterized by metastatic dissemination and outgrowth of 
drug resistant tumours. The ability of the infiltrated tumour cells to survive during latency and to 
reinitiate growth at the secondary site, when conditions are favourable, was reminiscent of cells 
having a CSC phenotype. 
The group of Weinberg found that both normal and cancer stem cells of the breast display 
features of epithelial-to-mesenchymal transition (EMT) features. EMT is a process by which 
epithelial cells lose their cell polarity and become mesenchymal cells to gain migratory and 
invasive properties. This process was first recognized as indispensable for embryogenesis. 
Indeed EMT, and its reverse process, the Mesenchymal-to-epithelial transition (MET) are critical 
for development of many tissues and organs in the developing embryo (Kong et al., 2011). The 
EMT is also involved in cancer, in particular during the metastatic process. Interestingly over-
expression of EMT transcription factors (such as Slug, Snail and Twist) or the down-regulation 
of epithelial markers (such as E-cadherin) not only induce an EMT program but also cause a 
concomitant enrichment in stem cells, as detected by different in vitro assays (Mani et al., 2008). 
In addition, enforced EMT in terminally differentiated mammary cells promotes a 
reprogramming to a bipotent stem cell able to generate an entire and functional mammary gland 
Accordingly, mammary stem cells have been shown to display mesenchymal traits instead of 
epithelial ones (Guo et al., 2012). 
 
The precise identification of the molecular bases that govern the self-renewal of normal 
mammary stem cells is important because these same pathways are thought to be required for the 
induction and maintenance of the CSCs and their aggressive phenotype. Inhibition of such 
signalling pathways has been proposed to be a novel and promising therapeutic strategy. In 
particular there is a considerable effort in finding therapies that target pathways, mutations or 
histological features that are common to all CSCs, overcoming breast cancer heterogeneity. A 







3.2. The prolyl-isomerase Pin1: a critical hub of phosphorylation-dependent 
pathway cross-talk 
 
Post-translational modifications (PTMs) represent a milestone process in biology (Prabakaran et 
al., 2012; Walsh, 2006). They are involved in many cellular processes, such as the control of cell 
cycle, apoptosis, transcription, cell commitment, metabolism and DNA repair. There are 
thousands of PTMs but, interestingly, phosphorylation on serine/threonine residues (phospho-
S/T) is the most prevalent one and it is a common way to process information in cells (Khoury et 
al., 2011). Phosphorylation of a protein involves the enzymatically, and reversible, mediated 
addition of a phosphate group to its amino acid side chains. In particular, phosphorylation of 
serine or threonine preceding a proline, represents a key signalling mechanism involved in many 
physiological and pathological processes (Lu and Zhou, 2007). Phosphorylation of these residues 
is a prerogative of Proline-directed protein kinases including glycogen synthase kinase-3, p38 
kinases, extracellular signal-regulated kinases and cyclin-dependent protein kinases. Proteins 
that have S/T-P sites phosphorylated adopt either a cis or a trans conformation, which implies 
that the same protein can perform different functions. The spontaneous conversion from one 
isomer to the other, i.e. uncatalyzed cis-trans isomerization is normally very slow and 
phosphorylation per se further decreases the already slow isomerization rate of prolines 
(Schutkowski et al., 1998). This reaction needs the intervention of the peptidyl-prolyl cis/trans 
isomerase Pin1 for a biologically relevant timescale cis/trans conversion to occur (Hunter, 1998).  
Pin1 belongs to the parvulin family of Peptidil Prolyl cis/trans Isomerases (PPIases). PPIases are 
a class of enzymes that catalyze conformational changes centered around proline residues and 
that include three structurally distinct subfamiles: the cyclophilins, the FK506-binding protein 
family and the parvulins (Galat, 2003). Notably, the only known human isomerase that 
specifically regulates the cis-trans conformation of Prolines only upon phosphorylation of the 
preceeding Serine or Threonine residues, is the parvulin Pin1 (Lu et al., 1996; Ranganathan et 
al., 1997; Yaffe et al., 1997).  
 
3.2.1 Pin1 structure and functional domains 
Human Pin1 is a 18KDa protein of 163 amino acids and its gene is located in chromosome 
19p13. Structurally, it is composed of two functional domains: an amino-terminal WW domain 
(amino acids 1-39) and a carboxy-terminal PPIase domain (amino acids 45-163) connected by a 
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short flexible linker region (Figure 5). For recognition and interaction with its targets on 
phospho-S/T-P sites, Pin1 requires the WW domain that is characterized by two conserved 
tryptophan residues and organized in a three-stranded antiparallel antiparallel β-sheet (Sudol and 
Hunter, 2000; Sudol et al., 2001). Subsequently the PPIase can interact with the phospho-S/T-P 
motifs and induce a cis-trans isomerisation of the peptide bond between the phosphorylated 
residue and the Proline. This enzymatic activity is mediated by a specific basic triad, composed 
by Lys63-Arg68-Arg69, that recognizes the negative charge present in the phospho-residues 
(Zhou et al., 2000).  
 
       
Figure 5. Pin1 structure and function 
The two-domain structure of Pin1 is shown in the upper part of the figure. The lower part of the figure shows the 
conversion of the target protein from cis to trans conformation and vice-versa (Yeh and Means, 2007).  
 
 
Pin1 was first identificated by a two-hybrid screening performed to identify proteins that interact 
with never in mitosis gene A (NIMA), a fundamental mitotic kinase in Aspergillus nidulans (Lu 
et al., 1996). Since overexpression of NIMA in yeast induces premature chromosome 
condensation and subsequently cell death and concomitant overexpression of Pin1 prevents this 
effect, it was suggested that Pin1 might be a regulator of mitosis.  
Pin1 is an evolutionarily conserved protein and was found to be fundamental in S. cervisiase, C. 
albicans and A. nidulans but not in X. laevis, D. melanogaster, M. musculus where its depletion 
is linked to some developmental defects (Crenshaw et al., 1998; Fujimori et al., 1999; Hanes et 
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al., 1989; Hsu et al., 2001; Maleszka et al., 1996; Winkler et al., 2000). Pin1 knock-out mice 
(Pin1-/-) have been generated in two different backgrounds. In the mixed background 
129SvJae/C57BL/6, Pin1-/- mice diplay premature aging and tissue defects, in particular 
decreased body weight, testicular atrophy, a dramatic retinal atrophy and alteration of the 
mammary gland that fails to undergo to proliferation during pregnancy (Liou et al., 2002). Mice 
in the inbred C57BL/6 background, display a reduced number of germ cells due to an alterated 
cell cycle in primordial germ cells (PGC), causing a decreased fertility both in males and females 
(Atchison and Means, 2003).  
 
3.2.2 Regulation of Pin1 levels and activity  
Even though no amplification or deletion of the PIN1 gene have been reported, the levels and 
functions of the protein are finely regulated by several layers of control under physiological and 
also pathological conditions. Some polymorphisms have been discovered, one of them, 
rs2233678 (-842G>C) in the Pin1 promoter that elicits reduced expression of the gene and is 
associated with a reduced risk of cancer in some human sub-populations (Han et al., 2010). 
Notably Pin1 expression is strongly associated with cell proliferation and cell cycle progression, 
since it is transcriptionally regulated by the E2F transcription factor in response to growth factor 
stimuli, Ras, and Her2/Neu (Ryo et al., 2002). In breast cancer cells, its mRNA levels are also 
upregulated by the Notch signalling pathway (Rustighi et al., 2009) and the Insulin-like growth 
factor (You et al., 2002). Accordingly, Pin1 mRNA and protein levels are increased in 
transformed cells (Bao et al., 2004). Recently, it has been reported that the apolipoprotein E4 is 
able to positively modulate Pin1 expression in the hippocampus and that this ApoE-Pin1 axis is 
involved in the pathogenesis of the Alzheimer disease (Lattanzio et al., 2014). Pin1 is also 
controlled by micro-RNA, in particular it is negatively controlled by miR-200b that promotes 
anoikis in breast cancer cells and is able to block metastatic progression (Zhang et al., 2013). It 
has become evident how pathways involved in pathologies such as cancer and Alzheimer 
mediate misregulation of Pin1 transcription. Consequently, Pin1 protein and mRNA levels are 
considered a prognostic and predictive marker for many diseases (Lu and Zhou, 2007). 
At a post-translational level, the enzymatic activity of Pin1, its cellular localization and turnover 
are finely regulated. Indeed a lot of kinases affect Pin1 functions by modifying its 
phosphorylation status (Liou et al., 2011). Activation of PKA phosphorylates Pin1 on Ser16 in 
the WW domain and inhibits its function by impairing its ability to interact with protein target 
and changing the sub-cellular localization (Lu et al., 2002b). This inhibitory phosphorylation on 
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Ser16 is mediated also by treatment with 12-O-tetradecnoylphorbol-13-acetate (TPA), that 
promotes an interaction between the 90-kDa ribosomal protein-S6-kinase 2 and Pin1 (Cho et al., 
2012). Another inhibitory phosphorylation occurs on Ser71 in the PPIase domain, and it is 
mediated by the Death-associated protein kinase1 (DAPK1). This phosphorylation blocks Pin1’s 
catalytic activity and nuclear localization (Lee et al., 2011). Despite a lot of kinases have an 
inhibitory effect on Pin1 activity, the mixed-lineage kinase 3 (MLK3) instead promotes Pin1 
catalytic activity and nuclear localization by adding phospate group to the Ser138 in the PPIase 
domain in breast cancer (Lee et al., 2011; Rangasamy et al., 2012). It is conceivable that an 
appropriate evaluation of the phosphorylation status of Pin1 in tissues will be more predictive of 
its activity rather than solely total protein levels.  
SUMOylation is another important PTM that affects Pin1’s activity, in particular it inhibits its 
functions when it occurs on Lys6 or Lys63. This inhinbitory effect is reverted by 
deSUMOylation by SENP1 which, in turn, increases Pin1 protein levels (Chen et al., 2013). 
 
3.2.3. Biological functions of Pin1 
As a consequence of its enzymatic nature, Pin1 requires a substrate to impact in any given 
cellular process. The peculiarity of a Pin1 target is the presence of a docking site constituted by a 
phosphorylated-Ser/Thr preceeding a Proline, which represents a key element in the signal 
tranduction. Indeed Pin1 interacts with and modifies a large number of proteins, impinging on 
several cellular processes such as cell cycle control, transcription, chromatin remodelling, cell-
fate commitment, DNA damage response, and metabolism. A growing body of evidence 
demonstrates that on one hand Pin1 acts as a hub that controls the dynamics of physiological cell 
behaviour by fine-tuning the cross-talk between phosphorylation signalling and cellular 
pathways. But on the other, its dysregulated expression in diseased conditions such as cancer, 
critically amplifies perturbed cell signalling, contributing to disease progression. 
 
3.2.3.1 Mechanisms through which Pin1 impinges on cellular processes  
The conformational changes induced by Pin1 on its protein substrates can have profound effects 
mainly on their stability, but also modulation of the catalytic activity, other PTMs like de-
phosphorylation, protein–protein interactions and subcellular localization have been described 
(Lu et al., 2002a).  
Pin1 has been shown to control protein turnover of many substrates by either favouring or 
blocking their recognition by several E3 ubiquitin-ligases. The phosphorylation of Ser/Thr-Pro 
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constitutes an important motif not only for Pin1 but also, when embedded within the socalled 
CDC4-phosphodegron, for specific recognition by the Skp1-Cullin-F-Box (SCF) complex that 
promotes the ubiquitination-dependent degradation of critical cellular substrates. Consequently 
Pin1 plays a major role in modulating the conformation of these proteins thereby affecting their 
interaction with the SCF complex and proteasomal degradation (Gutierrez and Ronai, 2006; Liou 
et al., 2011).  
Fbwx7α is a component of SCF complex and is also known as CDC4, AGO, SEL10. It is an 
important E3 ubiquitin-ligase that controls many cellular processes such as cell proliferation, 
stemness and differentiation, metabolism and apoptosis (Buckley et al., 2012; Welcker and 
Clurman, 2008; Wertz et al., 2011). It regulates a plethora of targets in many tissues such as 
Notch1, Notch4, c-myc, cyclin E, c-jun, MCL-1 and SREBP (Cheng and Li, 2012; Welcker et 
al., 2004). Fbwx7α recognizes a phospho-epitope, termed CPD (for Cdc4 Phospho-Degron), 
contained within these substrates. Via its F-box domain, Fbwx7α recruits the remainder of an 
SCF ubiquitin ligase complex, thus promoting substrate ubiquitination and proteasomal 
degradation. The eight WD40 repeats at the C-terminal end form a phospho-epitope binding 
pocket that can recognize and bind to phosphorylated CPDs. CPDs consist of a central 
phosphorylated threonine immediately followed by a proline (pT-P). Moreover a priming 
phosphate in the +4 position is required, that is provided by a phosphorylated serine, or a 
phospho-mimetic residue, in order to phosphorylate the central threonine (Welcker and Clurman, 
2008). 
Once phosphorylated, the CPD might become a Pin1 binding site. Indeed, many of the Fbwx7α 
targets are also Pin1 substrates and, consequently, Pin1 is impinging on their ubiquitination and 
protein degradation mediated by this ubiquitin-ligase (Liou et al., 2011). Notably the role of Pin1 
on the Fbxw7-mediated protein degradation is context- and tissue-dependent. Indeed it has been 
shown that on one hand Pin1 promotes protein stabilization of some targets, such as Mcl-1, on 
the other it promotes the degradation of c-Myc and cyclin E (Welcker et al., 2004). In addition it 
has been recently demonstrated, in colon cancer cells and fibroblasts, that Pin1 promotes auto-
ubiquitination and degradation of Fbwx7 (Min et al., 2012). Thus the effect of Pin1 on Fbxw7 
targets seems not to be unidirectional. 
Besides the Pin1-Fbwx7α dualism in the control of protein degradation, Pin1 is able to control 
the stability of many other proteins, such as cyclin D1, NF-κB, β-catenin, p53 family members, 
Nanog, Oct4, ErbB2, Akt, Smad proteins and Tau by different mechanisms (Liou et al., 2011). 
Alteration of their protein levels was shown to affect their activities and their ability to interact 
and cross-talk with their partners and regulators. As a result Pin1, through modulation of protein 
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stability, is able to impinge on several cellular processes. The best-studied biological function of 
Pin1 is undoubtedly regulation of cell cycle progression. Important roles for this enzyme in the 
control of a variety of other phosphorylation-dependent processes have been unveiled, some of 
which have been studied by us and are described in depth below. 
 
3.2.3.2 Cell-cycle control 
Pin1 was discovered as a regulator of mitosis (Lu et al., 1996; Yeh and Means, 2007). Further 
studies unveiled a role for Pin1 in all phases of the cell cycle. In fact, during cell cycle 
progression there is a precise timing and sequence of activation and inactivation of CDKs which 
are known to be phosphorylated on Ser/Thr-Pro motifs and, indeed, Pin1 fits perfectly in this 
molecular organization (Lu and Zhou, 2007; Nigg, 2001). The G0/G1-S phase transition dictates 
the entrance in the cell cycle and a key regulator of this passage is cyclin D1. Notably Pin1 
increases cyclin D1 levels in a bymodal manner, i.e. preventing its protein degradation and 
upregulating its trascription (Liou et al., 2002; Wulf et al., 2001). Another important step that 
occurs during the G1-S phase, is the coordination of centrosome duplication and DNA synthesis. 
Pin1 is localized in the centrosomes and induces their duplication; in breast cancer Pin1 over-
expression promotes chromosome aneuploidy as a consequence of deregulated centrosome 
amplification. Conversely, reduction of Pin1 levels strongly impaired centrosome amplification 
(Suizu et al., 2006). Accordingly, its protein levels are higher during the G1-S transition (Ryo et 
al., 2002) while Pin1-/- mouse embryonic fibroblasts exhibit defects in the G1-S transition 
(Fujimori et al., 1999). The role of Pin1 in the regulation of G1-S transition is more complex 
since it promotes the degradation of cyclin E at a later stage of the S phase (van Drogen et al., 
2006), thus suggesting that Pin1 is controlling the amplitude of the G1-S transition.  
During the S phase the RNA polymerase II is recruited on the promoters of transcribed genes 
while it is released in M phase. Notably Pin1 coordinates this dynamic association by directly 
binding the RNA polymerase II (Xu and Manley, 2007a). In particular, Pin1 controls also the 
G2-M transition, acting on the early mitotic inhibitor-1 and, consequently, on anaphase 
promoting complex (APC) thus coordinating the S and M phases (Bernis et al., 2007).  
Mitosis is promoted by cyclin B-CDC2 that, also in this case, is controlled by Pin1. In this case 
Pin1 indirectly controls cyclin B, acting on CDC25C and WEE1, regulators of the cyclin B-
CDC2 phosphorylation status (Okamoto and Sagata, 2007; Zhou et al., 2000). The impact of 
Pin1 in the M phase emerged also by the evidence that it interacts with topoisomerase IIα 
impinging on the G2-M phase transition (Xu and Manley, 2007b).  
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All this evidence supports the idea that Pin1 is a fine tuner of the cell cycle progression in which 
it calibrates the correct timing and quantity of factors that trigger initiation or termination of each 
single phase.  
 
3.2.3.3 Pin1 at the crossroads between stemness and differentiation 
The normal development of organisms and the maintenance of tissue integrity are guaranteed by 
a correct balance between differentiation and stemness (Chen and Daley, 2008; Keller, 2005; 
Yeo and Ng, 2013). During embryogenesis, the proper timing and specification of differentiation 
stimuli is fundamental for the commitment of embryonic stem cells to generate the three 
embryonic germ layers. A lot of studies have been done to understand the molecular basis of 
embryonic stem cells’ biology (ESCs) in light of a better comprehension of embryogenesis, of 
the pathways required by the CSCs and, recently, for their application in regenerative medicine 
(Yeo and Ng, 2013). In particular, manipulation of these molecular circuitries allowed the 
conversion of adult differentiated cells in pluripotent stem cells, called induced pluripotent stem 
cells (iPS)  (Takahashi and Yamanaka, 2006).  
It has been demonstrated that, beyond the up-regulation of important pro-stem factors such as 
Oct4, Nanog and Sox2 by transcriptional regulation and chromatin remodelling (Yeo and Ng, 
2013),their post-translational modifications, in particular phosphorylation and ubiqitination, are 
essential for a correct shift from a pluripotent to a differentiated fate and viceversa (Brill et al., 
2009; Buckley et al., 2012; Van Hoof et al., 2009). These evidences suggest that the ESC 
regulation is a plastic process governed by several layers of control in which small changes in 
ESC regulators are sufficient for a complete cell reprogramming (Yeo and Ng, 2013). In this 
scenario, the prolyl-isomerase Pin1, an important fine tuner of gene expression, protein levels 
and post-translational modifications (Liou et al., 2011; Lu and Zhou, 2007) emerged as an 
essential regulator of pluripotency and stemness both in ESC and iPS cells (Moretto-Zita et al., 
2010; Nishi et al., 2011). In particular Pin1 is indispensable for the induction and maintenance of 
pluripotency in iPS by interacting with phosphorylated Oct4, preventing its ubiquitination, 
boosting its protein levels and activity. Accordingly, Pin1 levels are higher in iPS and ablation of 
its activity suppresses colony formation in murine ESC cells (Nishi et al., 2011). Similarly, Pin1 
levels are higher in ESCs and its genetic or pharmacological ablation curbs their clonogenic 
potential. In ESCs Pin1 is boosting stemness by preventing the degradation of Nanog (Moretto-
Zita et al., 2010). 
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The impact of Pin1 in cell fate commitment carries several clinical implications. In particular, 
the major problem of iPSs is their intrinsic tumourigenic potential that has prevented their use in 
regenerative medicine (Takahashi and Yamanaka, 2006). This tendency could be controlled by 
modulation of Pin1 protein levels (Moretto-Zita et al., 2010; Nishi et al., 2011).  
The regulation of the transition from an undifferentiated stem cell to a differentiated state and 
viceversa mediated by Pin1 is maintained also in adult tissues with several consequences for the 
organogenesis. It has been demonstrated that Pin1-/- mice develop normally but display some 
defects in many compartments (Atchison and Means, 2003; Fujimori et al., 1999; Liou et al., 
2002; Shen et al., 2013). Different studies unveiled that these defects might be partially 
explained by a role of Pin1 as a master regulator of the cell commitment in many cellular types 
such as neurons (Ciarapica et al., 2014; Nakamura et al., 2012), skeletal muscle cells (Magli et 
al., 2010), primordial germ cells (Atchison and Means, 2003), adipocytes (Uchida et al., 2012), 
osteoblasts (Lee et al., 2013a)and dental pulp cells (Lee et al., 2013b). All this evidence 
pinpoints Pin1 as a cell-fate determinant.  
Interestingly, in adult tissues, Pin1 is not always linked to the maintenance of stem cells. Indeed, 
while in skeletal muscles it sustains the maintenance of undifferentiated cells, in the brain Pin1 
drives neuronal differentiation. In particular two different groups observed that Pin1 drives 
neuronal differentiation and its protein levels are higher in differentiated neurons during 
embryonic development, compared to less differentiated ones, without perturbing glia cells’ 
commitment (Ciarapica et al., 2014; Nakamura et al., 2012). This effect is mediated in a bimodal 
fashion: on one hand Pin1 interacts with β-catenin, a master regulator of neurogenesis, boosting 
its protein levels, on the other it cooperates with the protein kinase HIPK2 in antagonizing 
Gro/TLE1:Hes1, a protein complex involved in the inhibition of neuronal differentiation. As a 
result Pin1-/- mice display impaired neonatal motor activity. 
The ability of Pin1 in the regulation of the cell-fate commitment is not only restricted to 
alterations of its proteins levels but, in some cases, also through its sub-cellular localization 
(Magli et al., 2010). In skeletal muscle cells Pin1 is localized in the nucleus and acts as an 
inhibitor of differentiation by promoting degradation of the Myocyte Enhancer Factor 2C 
(MEF2C). Interestingly, during muscle cells’ differentiation, there is a shuttling of Pin1 from the 
nucleus to the cytoplasm with a concomitant rescue of the stability and transcriptional activity of 
MEF2C that, consequently, induces a differentiation program. 
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Based on these data, Pin1 can be clearly considered as a cell-fate determinant in the adult tissue, 
therefore alteration of its levels, activity or sub-cellular localization could compromise the 
integrity of many tissues. 
 
3.2.3.4 Pin1 pinpoints the cellular response to environmental stresses  
Cells exposed to genotoxic stress, chemical agents, or stimuli from the enviroment, undergo an 
adaptive response involving adjustments of the levels and activity of its genome-protecting 
protein machinery. When cell cycle checkpoints are switched on and stimulate DNA repair, cell 
cycle arrest, apoptosis or other processes are induced, depending on the stimulus and cell type. 
The p53 family members, in particular p53 and p73, are important tumour suppressors and are 
the major mediators of the cellular response to genotoxic insults and pharmacological treatment. 
Both p53 and p73 are subjected to proline-directed phosphorylation and are Pin1 targets 
(Mantovani et al., 2004; Mantovani et al., 2007; Zacchi et al., 2002; Zheng et al., 2002). In 
detail, Pin1 is able to prevent the interaction of p53 with its ubiquitin ligase Mdm2 thus enhances 
its half-life and, consequently, it increases cellular apoptosis upon genotoxic stress. The ability 
of Pin1 to potentiate p53 goes even beyond: on one hand Pin1 is required for a correct loading of 
p53 on its target genes and on the other it prevents the association of the apoptosis inhibitor 
iASPP (Mantovani et al., 2007). In addition, it has been recently demonstrated that Pin1, 
cooperating with HIPK2, promotes both p53 mitochondrial translocation and its transcriptional-
independent apoptotic activity (Sorrentino et al., 2013). Moreover Pin1 boosts also p73 protein 
levels and transcriptional activity since it promotes p73 acetylation and subsequent protein 
stabilization; this circuitry has an important role in tumours cells lacking p53 and treated with 
chemotherapeutic agents (Mantovani et al., 2004). Interestingly Pin1 is not only able to control 
the DNA controllers, but it is directly involved in the regulation of DNA integrity by modulation 
of DNA double strand break (DSB) repair mechanisms in response to DNA damage. In 
particular Pin1 promotes non-homologous end-joining (NHEJ) at the expense of homologous 
recombination (HR), directly impinging on the DSBs resection (Steger et al., 2013). 
 
The in vivo impact of these findings is still not so clear since many of these studies have been 
performed in primary fibroblasts and cells lines. It will be important to assess this issue, since 
Pin1 is often up-regulated in tumours (Bao et al., 2004) while p53 tumour suppressor activity is 
frequently abolished  (Levine and Oren, 2009). The fact that Pin1 is required for a more efficient 
p53-dependent apoptosis following genotoxic stress may have clinical relevance in tumors with 
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concomitatnt high Pin1 levels and wild-type p53 status, since in these tumors its activity might 
be restored (Hoe et al., 2014). 
Pin1 is not only able to drive the cellular response in genotoxic stress conditions, but also 
following oxidative stress. One of the major cellular mediators of this process is p66shc, which 
regulates cellular aging, apoptosis induction and the lifespan. As a consequence the knock-out 
mice models display longer life span and protection from oxidative stress (Migliaccio et al., 
1999). It has been demonstrated that Pin1 potentiates the mitochondrial accumulation of p66shc 
thus inducing apoptosis in response to ROS (Pinton et al., 2007).   
Thus, Pin1 is clearly an important modulator of the cellular response to environmental stresses 
acting through proteins of the DNA checkpoint and repair machinery and mediators of oxidative 
response.  
Tumour chemoresistance is emerging as a major problem for the eradication of tumors. Despite 
clinical advances in the last years, chemoresistance still remains a major cause of death and an 
unresolved issue. The resistance could be intrinsic, since some tumour cells do not respond 
properly to the chemoterapeutic regime, or acquired, since they are initially responsive to the 
chemotherapy but  become resistant later. In both cases cells display common features such as 
alteration of the pharmacological target, activation and expression of proteins that reduce the 
intracellular drug concentration, acquisition of the ability to change the cellular response by 
alterating the apoptotic pathway or DNA repair machinery, or they being tolerant to genotoxic 
stresses (Dean et al., 2005).  
Pin1 has been directly or indirectly linked to chemoresistance. First of all, Pin1 is overexpressed 
in tumours and its protein levels correlate with aggressiveness. Since the most aggressive 
tumours are often less responsive to chemotherapy it is conceivable that Pin1 is linked to 
chemoresistance (Ayala et al., 2003; Bao et al., 2004; Fukuchi et al., 2006; Wulf et al., 2001). 
Second, Pin1 is more expressed in some stem-cell subpopulations (Magli et al., 2010; Moretto-
Zita et al., 2010; Nishi et al., 2011) which are chemoresistant by definition (Visvader and 
Lindeman, 2012) thus, as consequence, Pin1 is linked to a chemoresistant subpopulation. Third, 
Pin1 interacts with several factors that have been separately linked to chemoresistance such as 
mutant-p53 (Muller et al., 2014), Notch1 (Rustighi et al., 2009), Mcl-1 (Ding et al., 2008), 
Nanog and Oct4 (Hu et al., 2010; Moretto-Zita et al., 2010; Nishi et al., 2011). Fourth, in breast 
cancer cell lines Pin1 has been directly linked to specific chemoresistance mechanisms (Ding et 
al., 2008). Indeed, it was discovered that Pin1 protects cancer cells from paclitaxel treatment, 
one of the most used and effective chemotherapeutic agents against breast cancer, through up-
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regulation of Myeloid cell leukemia-1 (Mcl-1), a Bcl-2–like antiapoptotic protein, involved in 
chemoresistance and tumourigenesis in several cancers. In particular, Pin1 is able to bind the 
Mcl-1 protein, upon phosphorylation by ERK, preventing its degradation and sustaining its 
protein levels. Notably Pin1 and Mcl-1 protein levels positively correlate in breast cancer patient 
samples. Despite all these publications, a real in vivo evidence of Pin1 in regulating the cellular 
response to environmental stresses is still missing. 
This bivalent and opposed role of Pin1 in cooperating both with proteins that promote apoptosis 
or protect cells from chemotherapy is due to its enzymatic nature and its biological output is 
strongly dependent on the availability of its targets. Specifically, tumours often display down-
regulation or loss of tumour-suppressors and concomitant activation of oncogenes and survival 
pathways, thus upsetting Pin1 to a more anti-apoptotic and tumour promoting role.  
 
3.2.4. Pin1 in cancer 
The first evidence of Pin1 in tumours has been reported in 2001 by two different publications in 
which Pin1 was found overexpressed in breast cancer (Ryo et al., 2001; Wulf et al., 2001). Later, 
high levels of Pin1 have been found in other tumours such as prostate, lung, colon, esophageal, 
human oral squamous cell, glioblastoma, ovary, cervical and melanoma cancers (Atkinson et al., 
2009; Bao et al., 2004; Jin et al., 2011; Miyashita et al., 2003). All these studies indicated a 
prominent role of Pin1 in boosting tumourigenesis through up-regulation of key oncogenic 
pathways (Lu and Zhou, 2007). Pin1 was revealed not only as a marker of tumourigenesis but it 
was also shown to correlate with poor prognosis in some cancer types (Ayala et al., 2003; 
Fukuchi et al., 2006; Girardini et al., 2011; Tan et al., 2010; Wulf et al., 2001).  
The first interactor of Pin1described in cancer is cyclin D1 as demonstrated by in vivo and in 
vitro experiments (Wulf et al., 2001). The nuclear localization and proteasomal degradation of 
cyclin D1 are controlled by a phosphorylation on Thr-286-Pro that is promoted by glycogen 
synthase kinase-3beta (GSK-3β). Pin1 was shown to bind to this motif upon phosphorylation, 
preventing nuclear export and subsequent degradation, maintaining high cyclin D1 protein 
levels. Notably Pin1 knock-out and cyclin D1 knock-out mice share similar phenotypes in 
particular in the mammary epithelium, where both fail to undergo to the massive proliferative 
change during pregnancy (Liou et al., 2002). 
The ability of Pin1 in boosting cyclin D1 levels goes even beyond an effect on protein 
stabilization. Indeed it has been demonstrated that the up-regulation of cyclin D1 induced by 
several signalling pathways such as the Ras, Her2/Neu, Wnt and NF-κB, requires the presence of 
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Pin1 which in turn is indispensable for full activity of these pathways (Liou et al., 2002; Lu and 
Zhou, 2007; Ryo et al., 2001; Ryo et al., 2003; Wulf et al., 2001). Pin1 can bind to 
phosphorylated c-Jun, β-catenin and NF-κB boosting their protein levels and transcriptional 
activity that is translated in high cyclin D1 gene expression. Moreover Pin1 is able to protect β-
catenin and NF-κB from their negative regulators, APC (adenomatous polyposis coli gene 
product) and IkappaB, respectively.  
Besides activation of growth factors receptors, one of the most important signalling pathways 
activated in cancer is the mitogen-activated protein kinase (MAPKs) cascade. In response to 
growth stimuli, Ras activates the Raf kinase, which in turn controls the MAPKs. As for other 
signalling pathways, this kinase cascade must be turned off by a negative feedback mechanism 
in which MAPKs phosphorylate and inactivate Raf. Notably Pin1 prevents this negative 
feedback, promoting Raf dephosphorylation with a consequent maintenance of an activated 
MAPKs cascade (Dougherty et al., 2005).  
 
All these data point out Pin1 as a fine tuner of signalling pathways in cancer, regulating their 
activation, counteracting their inhibitors and thereby boosting their mediators. The proof that 
Pin1 is strongly required by these pathways emerged also by the discovery that, in turn, they 
induce Pin1 gene transcription and that genetic ablation of its gene block, in vivo, their 
oncogenic potential. In particular, Her2/Neu and Ras induce E2F transcription and progression 
of the cell cycle; E2F is then recruited on the Pin1 gene promoter inducing its transcription (Ryo 
et al., 2002). Since E2F is not only regulated by these pathways but it is a marker and promoter 
of the G1/S transition, it is conceivable that whatever the stimulus that induces cell cycle 
progression, Pin1 transcription can be induced.  
Several reports have shown that Pin1 is also linked to aggressive traits of cancers. Indeed it has 
been demonstrated that Pin1 protein levels are higher in high-grade and more aggressive breast 
cancer subtypes (Wulf et al., 2001). In particular in triple negative breast cancer cell lines, Pin1 
cooperates with two other important oncogenes such as Notch1 (Rustighi et al., 2009) and 
mutant-p53 (Girardini et al., 2011). Notch1 is a membrane bound heterodimer receptor, normally 
inactive, that becomes cleaved and activate by γ-secretase upon interaction with its specific 
ligand (Ranganathan et al., 2011). Pin1 interacts with the Notch1 receptor and increases the 
cleavage mediated by the γ-secretase, allowing full activation of the pathway and boosting its 
oncogenic activity both in vitro and in vivo. Also in this case the oncogene stimulated by Pin1 is 
able in turn to transcribe Pin1 itself, since Notch1 is directly recruited on the Pin1 gene 
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promoter. As a consequence, in human breast cancer samples there is a strong correlation 
between high levels of activated Notch1 and Pin1 overexpression (Rustighi et al., 2009).  
Pin1 has also been linked to mestastasis, aggressiveness and poor prognosis in triple negative 
breast cancer through cooperation with mutant-p53, following oncogenic stress. In particular it 
has been described that Pin1 binds to a phosphorylated mutant-p53 in breast cancer cell lines 
where it co-regulates a transcriptional program, that promotes migration and metastasis 
formation in vivo and correlates with poor prognosis in breast cancer patients and. Ablation of 
Pin1 lowers the oncogenic gain of function of mutant-p53 with reduced formation of breast 
cancer metastases into the lung, suggesting interesting therapeutic opportunities (Girardini et al., 
2011).  
Another important Pin1 target involved in the metastatic process is the focal adhesion-associated 
non-receptor protein-tyrosine kinase (FAK) involved in cellular adhesion and cell migration. 
FAK becomes phosphorylated following oncogenic stress by a Ras-ERK axis on Ser910. This 
PTM recruits Pin1 on the FAK protein causing an association with the protein-Tyr phosphatase 
(PTP) (PTP-PEST) that in turn dephosphoryates FAK on Th397 inhibiting its activity. The result 
is the promotion of a migratory and invasive phenotype (Zheng et al., 2009). 
 
Besides all the evidence that Pin1 is required for full activation of oncogenic pathways, it’s 
conceivable that its effects go even beyond. Phosphorylation plays a fundamental role in 
regulating many intracellular processes such as growth, proliferation, cell division, apoptosis and 
differentiation. It is clear that perturbations of the phosphorylation status in a cell are likely to 
drive many of the hallmarks of cancer. Thereby, many cancers display deregulation or 
mutational events in kinases and phosphatases, and many of the genes encoding for these 
proteins are oncogenes or tumour suppressors. Accordingly, phosphorylation sites mutated by 
single nucleotide variants are found in almost 90% of tumours and, moreover, 29% of these 
mutations directly abolish phosphorylation or modify kinases’ target sites (Reimand et al., 2013). 
It is evident how Pin1 is strongly involved in this scenario, as a consequence of its way of action. 
It is unsurprising that modulation of Pin1 activity and levels could be comparable to deregulation 
or mutation in kinases and phosphatases, strengthening the idea that Pin1 is an oncogene. 
Accordingly, transgenic overexpression of Pin1 in mouse mammary glands leads to mammary 




3.3. The Notch signalling pathway 
 
The Notch pathway is a conserved signalling route indispensable for the development of 
multicellular organisms, based on interaction with ligands expressed on neighbouring cells that 
are required for its proper activation. Signals that activate this pathway boost initiation and 
amplification of molecular differences that promote the cell fate commitment (Artavanis-
Tsakonas et al., 1999). Activation of the pathway promotes the release of the nuclear activated 
form of Notch that translocates into the nucleus e transactivates several target genes. This 
pathway is involved in the regulation of many cellular processes such as proliferation, cell death, 
metabolism, angiogenesis, stemness and cell fate specification during development and renewal 
of adult tissues. As a consequence, alteration of this pathway is associated with pathological 
situation, such as developmental defects, cardiovascular disease and cancer (Bray, 2006; 
Ranganathan et al., 2011).  
 
3.3.1. Notch receptors and ligands  
In 1917, Thomas Hunt Morgan discovered a particular mutant of Drosophila with notches at the 
end of their wings. This trait was attributed to a partial loss of function of what have 
subsequently been described as the Notch gene that transcribes for a type I trans-membrane 
receptor. The human Notch homologue gene is located in the 9q34.3 chromosome and was 
cloned in the 1985/6 by two groups (Kidd et al., 1986; Wharton et al., 1985). In Drosophila there 
are only one single Notch protein and two ligands (Delta and Serrate), by contrast mammals 
display four Notch proteins Notch 1-4 and five ligands (Delta-like-1,-3 and -4, and Jagged-1,-2) 
(Radtke and Raj, 2003) (Figure 6). Notch receptors are produced as monomeric precursors that 
are subsequently processed by Furin protease in the trans-Golgi (called S1 cleavage) and 
exposed on the cell surface as heterodimers (Blaumueller et al., 1997). The heterodimer consists 
of a non-covalent association between the extra-cellular domain (NECD) and the intracellular 
portion that goes across the membrane and protrudes in the extracellular space (NTCIM). The 
extra-cellular domain contains both 36 tandemly repeated copies of an epidermal growth factor-
like motif, called EGF-like, required for the interaction with the ligands, a negative regulatory 
domain (NRR) composed by cysteins that prevents the inappropriate activation of the receptor in 
absence of its ligands and a heterodimerization domain (HD) that interacts with the extracellular 
part of NTMIC. The Notch intra-cellular domain, called NICD is released from the membrane 
and constitutes is the activated part of the cleaved heterodimer that mediates the majority of the 
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biological processes in which the Notch pathway is involved. NICD contains a RAM domain, 
necessary for interaction with transcriptional factors, seven ankyrin repeats, two nuclear 
localization signals, a trans-activation domain (TAD) and a PEST domain, enriched in proline, 
glutamate, serine and threnonine, that regulates the stability of the protein (Andersson et al., 
2011; Kovall and Blacklow, 2010) . 
 
                          
Figure 6. Structure of Notch proteins and their ligands 
a) Wing blade of a wild-type Drosophila melanogaster (left), and of a mutant with a partial loss of the Notch gene 
(right). The notches, which are absent in the wild type, but clearly visible at the border of the wing blade, have given 
the name to the implicated gene. b) Structure of Notch proteins and their ligands. Drosophila has one Notch 
receptor (dNotch) and vertebrates have four (Notch1–4), which are presented on the cell surface as heterodimers. 
The ectodomain of Notch receptors contains epidermal-growth-factor (EGF)-like repeats and a cysteine-rich 
Notch/Lin12 domain (LN); this is followed by a transmembrane domain, the RAM domain and six ankyrin repeats 
(ANK, also known as CDC10 repeats), two nuclear-localization signals (NLSs), followed by the transactivation 
domain (TAD) and a PEST sequence. c) Two transmembrane-bound ligands for Notch have been identified in 
Drosophila, named Delta (Dl) and Serrate (Ser). The vertebrates possess three Delta homologues, called Delta-like 
(DLL)-1, -3 and -4, and two Serrate homologues, Jagged 1 (JAG1) and Jagged 2 (JAG2). The ligands harbour an 
amino-terminal structure called DSL (Delta, Serrate and LAG-2), which is common to all family members, followed 
by EGF-like repeats. Serrate, Jagged1 and Jagged2 harbour a cysteine-rich domain (CR) following the EGF-like 







3.3.2. Notch pathway activation 
Notch signalling is initiated by a receptor-ligand interaction between two neighbouring cells. 
Notably it has been recently demonstrated that also soluble forms of ligands forms exist, that can 
activate Notch signalling in non neighbouring cells, suggesting other possible levels of cellular 
communications (Lu et al., 2013a). The interaction between the ligand and the receptor is an 
essential step for the Notch signalling activation, since it induces a conformational change in the 
receptor that allows the cleavage and the subsequent release of a citoplasmic activated form that 
translocates in the nucleus and activates its target genes. Following interaction with the ligand, 
the receptor is cleaved by the disintegrin and metalloprotease ADAM10 or ADAM17 that 
constitutes the S2 cleavage (Bray, 2006; Brou et al., 2000; Fortini, 2002). The subsequent 
cleavage within the trans-membrane domain of Notch is mediated by the multisubunit protease 
called gamma secretase that contains presenilin, nicastrin, PEN2 and APH1. This cleavage (S3 
cleavage) results in the release of the Notch intra-cellular domain called NICD (Figure 3).  
In the canonical pathway NICD translocates in the nucleus and cooperates with the DNA-
binding protein CSL (CBF1, Su(H) and LAG-1) and its co-activator Mastermind to promote 
transcription of its target genes such as HES-1, HEY-L and cyclin D1 (Radtke and Raj, 2003). In 
the absence of NICD, CSL already bound to the promoters of Notch target genes, recruits co-
repressors and histone deacetylases with a consequent inhibition of transcription (Kao et al., 
1998). When NICD is activated and present in the nucleus it competes with the repressors for 
CSL binding, displaces them and converts CSL from transcriptional repressor to an activator 
(Bray, 2006; Fryer et al., 2002). 
While Notch mediates a number of biological processes through the canonical pathway, ligand- 
or transcription-independent functions are emerging that may have and unprecedented impact in 
development and disease (Andersen et al., 2012). 
 
3.3.3 The Notch pathway regulation 
Although the intracellular transduction of the Notch signal is remarkably simple, with no 
secondary messengers, there is an enormous complexity in its regulation to keep in check the 
amount and timing of its activation. Such regulation is essential since Notch controls both the 
transcription and the function of genes and proteins involved in many cellular processes. Indeed 
alteration of these checkpoints is associated with developmental defects and diseases (Grabher et 
al., 2006; Ranganathan et al., 2011). 
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Notch signalling is modulated in many ways during maturation and upon activation such as 
through post-translational modifications of both receptors and ligands, endocytosis, 
ubiquitination and receptor maturation (Le Borgne et al., 2005) (Figure 7). Numb, a cell fate 
determinant is a known inhibitor of the Notch pathway. Numb is an endocytic adaptor protein 
that acts as a suppressor of Notch signalling (Knoblich et al., 1995; Uemura et al., 1989). 
Mechanistically, Numb has been shown to recruit the E3 ubiquitin ligase Itch, the mammalian 
homolog of Drosophila Suppressor of deltex (Su(Dx)), to promote the degradation of the Notch 
receptor and to regulate post-endocytic sorting events for Notch (McGill et al., 2009; McGill and 
McGlade, 2003). Numb differentially affects various Notch receptors, since it negatively 
regulates Notch1 and Notch2 receptors, but not Notch3, during myogenic differentiation (Beres 
et al., 2011). In human, six alternatively spliced NUMB isoforms have been characterized to 
date. The two most recently identified isoforms, NUMB5 and NUMB6, are less potent 
antagonists of Notch signalling (Karaczyn et al., 2010), although it remains to be established if 
the difference in biological effects among the different isoforms is strictly due to different effects 
on Notch, as Numb also interacts with other signalling proteins, such as p53, Gli1, and 
Hedgehog pathway effectors (Colaluca et al., 2008; Di Marcotullio et al., 2006). There is 
emerging evidence that the relationship between Numb and Notch is not unidirectional. Indeed it 
has been shown that Notch also can influence Numb since high levels of Notch reduce Numb 
protein levels (Chapman et al., 2006). 
Another important inhibitor of the Notch pathway is the E3-ubiquitin ligase and tumour 
suppressor Fbwx7α (Gupta-Rossi et al., 2001; Oberg et al., 2001). As mentioned before, 
activation of the Notch signalling promotes the cleavage and the translocation into the nucleus of 
the NICD that recruits Mastermind for a proper activation of its target genes. Notably, the trans-
activation complex recruited by NICD on one hand promotes Notch target genes’ transcription, 
on the other it promotes its own turn-over. Indeed Mastermind recruits the CDK8/CycC that 
promotes NICD phosphorylation thus triggering recognition by Fbwx7α and the subsequent 




       
 
  
Figure 7. Notch pathway activation and regulation 
a-b) Notch is produced as a monomer and it is glycosylated by O-fucosyltransferase1 (OFUT1) at the endoplasmic 
reticulum (ER) thus into the Golgi for the subsequent cleavage mediated by Furin protease. c) This results in a 
heterodimeric receptor with non-covalently associated domains that is transported to the plasma membrane. d) 
Ligand binding initiates two successive proteolytic cleavages (S2 and S3). The first, mediated by an ADAM 
proteinase (a disintegrin and metalloproteinase domain), occurs in the extracellular domain. S2 cleavage allows 
access of the gamma-secretase complex, which is responsible for the second proteolytic cleavage (S3), which occurs 
within the transmembrane domain and liberates the intracellular domain (ICN) e) The ICN translocates to the 
nucleus, where it interacts with the CSL transcription factor. Numb suppresses Notch signalling, possibly by 
preventing nuclear localization and targeting the ICN for degradation through the E3 ligase Itch. g) The stability of 
nuclear ICN is regulated through its PEST domain (enriched in proline, glutamate, serine and threonine). Binding of 
MAML to p300 and cyclin-dependent kinase 8 (CDK8) promotes hyper-phosphorylation of the ICN PEST domain 
to facilitate ubiquitylation, through recruitment of Fbwx7αα E3 ligases, which target the ICN to the proteosome 
(Grabher et al., 2006). 
 
 
Fbwx7α is an important E3 ubiquitin-ligase that controls, besides N1-ICD, the turn-over of many 
other important transcription factors, by recognition of the phosphorylated CPD motif. The 
Notch1 CPD is located in the PEST domain, it is constituted by FLTPSPESP residues and it is 
centred on threonine 2512. Indeed substitution of this threonine with an alanine disrupts the 
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interaction of N1-ICD with Fbwx7α (Thompson et al., 2007). Since NICD is the final mediator 
of activated Notch signalling, the regulation of its amount is of utmost importance as emerged by 
the evidence that mouse models knock-out for Notch or Fbwx7α are similar since they die in 
utero for the same cardiovascular disease (Swiatek et al., 1994; Tetzlaff et al., 2004; Tsunematsu 
et al., 2004). In addition, in about 50% of human T-cell acute leukaemias and lymphomas (T-
ALL) (Weng et al., 2004), some of which disrupt binding to Fbwx7α. Notably, in some cases, T-
ALLs harbouring NOTCH1 activating mutations and treated with the gamma-secretase inhibitor 
(GSI), were resistant to the pharmacological treatment because of mutation on Fbwx7α that 
impaired its ability to bind N1-ICD (O'Neil et al., 2007; Thompson et al., 2007).  
 
3.3.4.  Biological functions of the Notch pathway  
Notch biological functions are fundamental during both embryogenesis and regulation of adult 
tissues in many organisms, through transcription of its target genes and cooperation with other 
signalling pathways (Ranganathan et al., 2011). 
While the genetic ablation of Notch1 or Notch2 induces premature embryonic death, the absence 
of Notch3 or Notch4 does not induce this phenotype suggesting a non-redundant role for 
Notch1/2 (Conlon et al., 1995; Krebs et al., 2003; Swiatek et al., 1994). During embryogenesis 
the cooperation with Wnt, SHH and TGFβ signals is required for promotion of an epithelial-to-
mesenchymal transition (EMT) resulting in upregulation of the Snail/SLUG transcriptional 
factor and down-regulation of E-cadherin (Grego-Bessa et al., 2004; Timmerman et al., 2004).  
Notch is one of the major cell-fate determinants in particular during neurogenesis. Indeed cells 
that over-express the Notch ligands will be committed to neuronal differentiation, while cells 
that express the receptors will acquire epidermal traits (Artavanis-Tsakonas et al., 1999). 
Another compartment in which Notch drives differentiation is the hematopoietic system, in 
particular in lymphocytes’ precursors, in which it promotes activation of PDK1 and mTOR with 
a consequent differentiation and proliferation as T cells (Kelly et al., 2007). By contrast 
lymphocytic precursors in which the Notch pathway is turned off, will acquire B cell features 
(Osborne and Minter, 2007). In addition Notch has a role in the cardiovascular system, 
regulating vasculo- and artherio-genesis by cooperation with VEGF and HIF1α, respectively 
(Holderfield and Hughes, 2008; Pear and Simon, 2005). 
The ability of Notch signalling to drive cellular fate persists also during adulthood 
(Androutsellis-Theotokis et al., 2006; Molofsky et al., 2004). Indeed the stem cell compartment 
of many adult tissues, such as the hematopoietic, breast, muscular and intestinal one requires 
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Notch activation for a proper regulation and of cell-specification. This process is a consequence 
of the interplay between Notch with other signalling pathways and an inappropriate deregulation 
of this well controlled mechanism could cause an unbalance in the stem cell compartments, as 
occurs in cancer (Ranganathan et al., 2011).  
The Notch regulators can have both positive and negative effects on the Notch pathway 
activation. In this context well known interactors of Notch are the p53 family members (Dotto, 
2009). Notch and p53 counteract each other at multiple levels regulating many cellular 
processes. In addition, another member of the p53 family, p63 has been demonstrated to curb the 
Notch signalling both in mammary stem cells and in epithelial cells where it blocks the Notch-
induced EMT (Yalcin-Ozuysal et al., 2010). On the contrary, enforced Notch activation impairs 
p63 cellular functions with a consequent transformation process (Mazzone et al., 2010).  
The result is an involvement of the Notch signalling in the regulation of stemness, proliferation, 
apoptosis, differentiation, EMT, angiogenesis, tissue homeostasis, which, when alterated, are 
associated with tumourigenesis pointing out Notch as an oncogene (Miele et al., 2006; 
Ranganathan et al., 2011). 
 
3.3.5. Notch and cancer 
The role of Notch in cancer is strongly dependent on the cellular context. Indeed, in the skin, 
Notch is an important tumour suppressor, mainly by blocking p63 functions (Dotto, 2008). 
Notably in many other tissues, Notch emerges as a master oncogene. The first evidence of a role 
of Notch in cancer, has been done in 1987, in human T-cell acute lymphoblastic leukemia (T-
ALL) in which there was a translocation involving the Notch locus on chromosome 7 and the T-
cell-receptor-beta on chromosome 9 (Reynolds et al., 1987). The consequence of this 
translocation is the aberrant transcription of a truncated Notch1 protein that corresponds to the 
nuclear active form, N1-ICD. Very frequent point mutations have subsequently been found 
mainly in T-ALL, in particular on the heterodimerization and PEST domains, causing ligand-
independent activation and protein stabilization, respectively (O'Neil et al., 2007). In T-ALL, 
Notch1 regulates two important proteins involved in tumourigenesis such as c-Myc and PTEN, 
in an opposite fashion: on one hand Notch1 directly activates c-Myc transcription and on the 
other PTEN gene expression is dampened by the transcriptional repressor Hes1, one of the most 
important mediators of the Notch pathway (Palomero et al., 2008; Palomero et al., 2006; Weng 
et al., 2006). In this way, Notch controls multiple cellular processes such as differentiation, 
transformation, metabolism, apoptosis, boosting tumourigenesis. After the discovery of its 
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involvement in T-ALL, Notch signalling has been implicated in various solid tumours, including 
breast cancer, medulloblastoma, colorectal cancer, pancreatic tumour and non–small cell lung 
carcinoma (NSCLC) (Miele et al., 2006).  
With exception of NSCLC, in all these solid tumours deregulated Notch activity results mainly 
from over-activation in absence of mutations. In particular it has been demonstrated that up-
regulation of the Notch pathway in 30% of NSCLS is caused by loss of Numb expression, while 
in 10% of cases is caused by gain-of-function mutations of the NOTCH-1 gene (Westhoff et al., 
2009) suggesting an important role of the Notch pathway in this tumour type.  
The oncogenic potential of Notch activation in solid tumours was first observed in mouse 
mammary tumor virus (MMTV)–driven breast cancer. The integration of MMTV in specific loci 
of the host genome results in dysregulated expression of adjacent genes and subsequent 
outgrowth of tumorigenic clones (Dievart et al., 1999). Characterisation of one of these loci 
revealed expression of a truncated constitutively active form of Notch4 (Gallahan and Callahan, 
1987; Gallahan et al., 1996). In mouse models, Notch activation can clearly drive mammary 
tumours, and in human breast cancers increased expression of Notch and Jagged1 correlates with 
poor prognosis (Reedijk et al., 2005). Loss of Numb expression causes over-activation of Notch 
signalling and tumourigenesis also in a large part of breast cancers (Pece et al., 2004). In breast 
tumours Notch has been demonstrated to functionally cooperate with several proteins for which 
a role in breast tumourigenesis has been well enstablished such as ErbB2, Ras signalling, Pin1, 
cyclin D1 and c-Myc (Miele et al., 2006; Ranganathan et al., 2011).  
The impact of Notch in breast tumours patients, derives from the evidence that Notch plays a 
major role in driving malignant phenotypes including EMT features, CSCs, metastases and 
chemoresistance, as assessed also by analyses of overall survival (Rizzo et al., 2008). 
In normal breast stem cells the role of Notch1 is well established since it was shown to trigger 
luminal progenitors’ formation by several groups. Consistent with this function in normal 
mammary stem cells and progenitors, the Notch pathway controls also breast CSCs. It seems that 
while Notch1 is mainly expressed and required for the early progenitors, Notch4 in more 
expressed in the CSC pool (Bouras et al., 2008; Dontu et al., 2004; Harrison et al., 2010). 
Accordingly, genetic and pharmacological abrogation of the Notch pathway in breast cancer 
cells is effective in curbing the CSCs pool.  
The ability of activated Notch receptors to promote also chemoresistance is not simply a 
consequence of an increased CSC/progenitor population. Indeed Notch has well-established 
roles in different mechanisms of chemoresistance as a consequence of the promotion of cell 
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survival factors such as BIRC5 (SURVIVIN), Bcl-2, and drug efflux pumps such as ABCG2 
(Bhattacharya et al., 2007; Ranganathan et al., 2011). Thus abrogation of Notch signalling 
sensitizes both cancer cells and CSCs to chemotherapeutic agents (Espinoza et al., 2013).  
Notch has been clearly linked to EMT features and metastases in breast cancers with in vitro and 
in vivo experiments. It has been demonstrated that Notch induces Slug gene transcription, with a 
consequent E-cadherin decrement, that results in an increased migratory and invasive ability 
(Leong et al., 2007). Recently it has also been demonstrated that activation of the Notch pathway 
affects the breast cancer secretome and promotes the metastases formation in the brain. Notably 
pharmacological ablation of Notch activation prevents this effect (Xing et al., 2013). 
It is evident that Notch is a candidate druggable pathway in cancer since it is enzymatically 
controlled at many levels and it is linked to aggressiveness phenotypes such as chemoresistance, 
tumourigenesis and CSCs maintenance and involvement of this pathway in breast CSCs’ biology 
warrants further investigation.  
Aim of the thesis 
 
4. AIM OF THE THESIS 
 
A major issue of breast cancer management is the failure of therapeutic regimens and disease 
relapse. These features are widely suggested to be promoted by cancer stem cells’ 
subpopulations. It is conceivable that genetic or pharmacological ablation of molecular pathways 
required for breast CSCs induction and maintenance, will exhaust this cell population with a 
consequent gain in sensitivity to chemotherapy. Moreover, the abrogation of this molecular 
signalling will prevent reprogramming of terminal differentiated cells to a more stem-like 
phenotype, blocking the selection of a chemoresistant and aggressive cancer cell population. 
The aim of my PhD work was to discover factors that might underlie all these aspects in breast 
CSCs. A putative candidate for such a role is the prolyl-isomerase Pin1 since i) it is 
indispensable for full activation of oncogenic signalling pathways ii) its protein levels are up-
regulated in high-grade breast cancers which exhibit an elevated CSCs content and iii) Pin1 is a 
stemness factor in embryonic stem cells and some adult tissues.  
The first part of this study will focus on the role of Pin1 in the maintenance of normal mouse 
mammary stem cells ex vivo and in vivo. As normal stem cells and CSCs display considerable 
similarities in their molecular regulators, the subsequent part will be aimed at dissecting how 
Pin1 controls and orchestrates breast CSCs number, maintenance and aggressive traits in vivo 
such as tumourigenesis and chemoresistance.  
In the second part we will investigate which is the functional mediator of the Pin1 promoted 
CSCs maintenance. In particular this study will focus the attention on how Pin1 potentiates the 
Notch pathway by safeguarding Notch1 and Notch4 nuclear active forms from their E3-
ubiqutitin-ligase Fbxw7α. Thereafter we will investigate the impact of the Pin1-Notch1/4 axis in 
tumourigenesis, CSC maintenance with in vitro and in vivo analyses in mouse models and in 
human breast cancer samples. 
These studies, collectively, might be relevant for providing the rational for a therapeutic strategy 









5.1 The prolyl-isomerase Pin1 is required for the self-renewal of normal mammary stem 
cells 
 
Pin1 knock-out mice display a variety of developmental defects. In particular the mammary 
epithelium of these mice fails to undergo the dynamic changes required for its expansion during 
pregnancy (Liou et al., 2002). Since it has been demonstrated that some of these defects are a 
consequence of an impaired stem cell function (Atchison and Means, 2003), we hypothesized a 
possible function of Pin1 in the regulation the mammary stem cell compartment. For this aim we 
decided to evaluate the mammary stem cell number of wild-type (Pin1+/+) and Pin1 knock-out 
(Pin1-/-) mice. Mammary tissues from 8-10 weeks old virgin female mice were dissociated, 
prepared as single cell suspensions of purified, lineage-depleted epithelial cells (Stingl et al., 
2006) and grown in suspension cultures to form secondary mammospheres (M2) (Dontu et al., 
2003). We detected a significant reduction in the spheres’ formation in absence of Pin1, since 
cells obtained from Pin1+/+ mice formed an average of 22.9 (±1.44) M2 mammospheres per 
100.000 seeded cells, while those from Pin1-/- cells gave rise to only 13.53 (±2.49), indicating a 
40% reduction of M2 formation  (Figure 8A). 
                             
Figure 8. Ablation of Pin1 reduced the mouse mammary epithelial stem cells number 
A) Left panel: Number of secondary mammospheres (M2) generated from primary mammary epithelial cells of 
indicated mice. Right panel: representative M2 microscope images with 200 µm scale bar. B) Serial replating of 
mammospheres (M1-M5) generated from Pin+/+ mice treated with DMSO or PiB (1,5 µM). Means, standard 
deviations and p-values (t-test, n=4) are indicated in the histogram 
 
It is known that the microenvironment is important to control the stem cell compartment’s 
homeostasis (Valent et al., 2012). To determine if the reduced stem cell number in Pin1-/- mice 
was due to an effect of Pin1 specifically in the mammary stem cells or in the microenvironment, 
we performed with Pin1+/+ mammary epithelial cells an ex vivo mammsophere experiment by 
blocking in vitro the enzymatic activity of Pin1. We serially replated cells from M2 to tertiary 
Results 
 
and quaternary mammospheres (M3, M4) in presence or absence of the Pin1 inhibitor PiB 
(Uchida et al., 2003) (Figure 8B).  
As expected in these conditions, we observed a progressive decrease in mammosphere formation 
efficiency (MFE) at each passage, due to exhaustion of adult stem cells (Cicalese et al., 2009). 
Notably, this effect was exacerbated by almost 50% at the M4 stadium upon addition of the Pin1 
small molecule inhibitor PiB. These data suggest that inhibition of Pin1 can directly inhibit the 
stem cell self-renewal of mammary stem cells.  
 
This evidence indicates a role for Pin1 in determining self-renewal and replicative potential of 
mammary stem cells thus implying alterations of the mammary stem cell compartment in Pin1-/- 
mice. To better address this point we analyzed the mammary epithelial stem cells hierarchy in 
Pin1+/+ and Pin1-/- mice by detection of specific immune phenotype markers, CD24 and CD49f, 
that identify both stem/bipotent progenitors (CD24med/CD49fhigh or mammary repopulating 
units, MRU) and luminal progenitors (CD24high/CD49flow or mammary colony forming cells, 
Ma-CFCs) (Stingl et al., 2006). In line with our hypothesis, the MRU and Ma-CFC cell 
populations from Pin1-/- mammary glands were present at lower proportion as compared to 
Pin1+/+ mice (Figure 9A).  
 
Figure 9. Bipotent stem cell and luminal progenitor number is decreased in Pin1-/- mammary tissue 
Bipotent stem cell and luminal progenitor number is decreased in Pin1-/- mammary tissue. Left panel: representative 
FACS analyses of mammary epithelial cells from indicated mice. CD24/CD49f plots and gatings for MRU and Ma-
CFC populations are indicated. Right panel: histogram of mean counts of MRU and MA-CFC populations from Pin-
/- normalized to Pin1+/+ mice. Means, standard deviations and p-values (t-test, n=3) are indicated. 
 
To demonstrate that the analyzed populations were indeed MRUs and Ma-CFCs, we sorted these 
two populations by FACS and analyzed the expression of specific myoepithelial (SMA, CK14) 
or luminal (CK-18, CK-19) markers, that are mainly expressed in the stem cell and progenitor 
populations, respectively (Stingl et al., 2006). As shown in Figure 10, Ma-CFC and MRU cells 
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sorted from the mammary epithelial cell population expressed higher levels of CK-18, CK-19 or 
SMA and CK-14, respectively, when compared to unsorted cell population (TOTAL). 
 
Figure 10. Molecular characterisation of the sorted MRU and Ma-CFC mammary epithelial cells. 
Control qRT-PCR for myoepithelial (SMA, CK14) and luminal (CK18, CK19) markers of mRNA extracted from 
MRU and Ma-CFC (Stingl et al., 2006) sorted populations relative to the total population, shows accuracy of the 
FACS sorting procedure. 
 
Many stem cells factors, such as Slug and Pin1 itself, are more expressed and active in the stem 
cell compartments (Guo et al., 2012) (Moretto-Zita et al., 2010; Nishi et al., 2011). For this 
reason we compared Pin1 mRNA and protein levels in the stem cells’ compartment with their 
differentiated counterpart. Interestingly, we found almost three times higher Pin1 levels in the 
MRU cell population as compared to the total of mammary epithelial cells (Figure 11).  
This evidence confirmed our hypothesis and suggests a prominent role of Pin1 in sustaining the 
mammary stem cell compartment in vivo. 
 
Figure 11. Pin1 mRNA and protein levels are upregulated in the mammary stem cell compartment.  
Left panel: qRT-PCR of endogenous Pin1 mRNA in MRU sorted populations relative to total population. Means, 
standard deviations and p-values (t-test, n=3) are indicated. Right panel: Western blot analysis of the same cell 
populations as in the left panel. Fold change in Pin1 protein levels determined by Image J software with respect to 





5.2 Pin1 inhibition impairs mouse and human cancer stem cells traits 
Molecular pathways required for normal mammary stem cells’ maintenance are often 
indispensable also for CSCs (Valent et al., 2012; Visvader and Lindeman, 2012). Thus many of 
these pathways are up-regulated also in the CSCs. Since we demonstrated that Pin1 is 
indispensable for the maintenance of normal stem cells, we investigated whether Pin1 could have 
a role also in the regulation of breast CSCs.  
For this aim we performed mammosphere formation with NOP6 mouse mammary cancer cells, 
harbouring a Her2/Neu amplification, for serial passages, in presence or absence of the Pin1 
inhibitor PiB. Interestingly Pin1 inhibition strongly impaired the formation of mammospheres at 
each passage, indicating that Pin1 is required for the self-renewal of mouse mammary cancer 
stem cells (Figure 12).  
 
Figure 12. Pin1 inhibition curbs mouse mammary CSCs maintenance. 
Serial repleating of mammospheres from M1 to M4 generated from NOP6 cells trated with DMSO or Pib (1,5µM). 
Mammosphere formation efficiency (%MFE) was calculated as percentage of mammospheres divided by the 
number of plated cells. 
 
 
To verify if Pin1 is required also by human breast cancer stem cells, we infected the triple 
negative breast cancer cell line MDA-MB-231 with a doxycycline-inducible knockdown 
lentiviral construct for Pin1 (pLKO-TetO-shPin1) and tested their ability to generate 
mammospheres. As shown in Figure 9A, while MDA-MB-231 MFE remained constant 
throughout serial replating to M4, the formation of mammospheres from Pin1 silenced cells 
(+DOX) progressively decreased at each passage. Accordingly the content of putative stem cells 
was lower following Pin1 silencing or inhibition, as confirmed by the Aldefluor assay, that 
valuates the activity of Aldehyde dehydrogenase 1 (Aldh), a marker for breast CSCs (Ginestier 
et al., 2007) (Figure 13A). Accordingly, Pin1 pharmacological inhibition curbed not only MDA-
MB-231 mammospheres formation but also the MFE of other breast cancer cell lines such as and 
BT-549 and SUM-159 (Figure 13B). These observations could be extended also to two patient-
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derived aggressive breast cancers, whose CSCs were reduced by Pin1 inhibition (Figure 13C). 
All these data demonstrate that genetic or pharmacological ablation of Pin1 impairs breast CSC 





Figure 13. Pin1 inhibition curbs human mammary CSCs traits. 
A) Left panel: MFE of MDA-MB-231-pLKO-shPin1 control cells (Ctrl) compared to shPin1 induced cells (DOX) 
upon serial passages. Right panel: Quantification of Aldh-positive and Aldh-negative cells from control- and shPin1 
induced M4, as assessed by FACS. B) Left: Serial replating of mammospheres (M1-M4) generated from MDA-MB-
231 human breast cancer cells and treated with DMSO or PiB (1,5 µM and 3 µM). Mammosphere formation 
efficiency (%MFE) was calculated as percentage of mammospheres divided by the number of plated cells. Means, 
standard deviations and p-values are indicated (t-test, n=3, M4). Right: Percentage of M2FE of BT-549 and SUM-
159 breast cancer cell lines treated with vehicle (DMSO) or PiB. Means, standard deviations and p-values are 
indicated (t-test, n=3). C) Secondary and tertiary mammosphere formation efficiency of a grade 2 (G2) and grade 3 




Conversely, overexpression of Pin1 in MDA-MB-231 cells increased M2 formation by almost 
two fold and produced an increase of Aldh-positive cells, when compared to empty vector 
harbouring cells (Figure 14).  
 
Figure 14. Pin1 over-expression boosts human mammary CSCs traits. 
Left: Secondary mammosphere formation efficiency of MDA-MB-231 cells transduced with empty or HA-Pin1 
expressing vectors. Representative microphotographs and scale bars are shown. Right: Histogram showing 
percentage of Aldefluor median fluorescence intensity difference (MFI). 
 
To unveil the molecular mechanism underlying the role of Pin1 in promotion of CSCs, we 
evaluated the expression of several genes acting within pathways that govern the stemness 
phenotypes of breast CSCs (Leong et al, 2007; Yu et al, 2007, 2011; Polyak & Weinberg, 2009; 
Cordenonsi et al, 2011; Visvader & Lindeman, 2012) in Pin1-silenced quaternary 
mammospheres. Interestingly, as shown in Figure 11, no single pathway emerged alone, as the 
expression of all tested factors (Hes1, HeyL, Birc5, CTGF, Slug, ABCG2, Ptch, Bmi-1, HMGA2 
and Klf4) decreased by Pin1 knockdown thus suggesting a common down-regulation of 
stemness signalling pathways following Pin1 depletion.  
Epithelial-mesenchymal plasticity in breast carcinoma has recently been linked to acquisition of 
stem cell traits by tumor cells (Mani et al, 2008). We therefore also analysed the impact of Pin1 
modulation on this process by analyzing markers of epithelial-to-mesenchymal transition (EMT). 
Of note, Pin1 downmodulation caused enhanced mRNA expression of the epithelial marker E-
cadherin (CDH1) while that of mesenchymal markers Vimentin and Fibronectin (VIM1, FN) 
was reduced (Fig 2C, left panel), in parallel with a strong recovery of E-cadherin and decay of 





Figure 15. Pin1 depletion reduces stem cell and mesenchymal marchers 
Left panel: qRT-PCR of the indicated stemness and EMT marker genes from MDA-MB-231-pLKO-shPin1 
quaternary mammospheres (M4) upon shPin1 induction (DOX) with respect to control cells (Ctrl). Standard 
deviations are indicated, P-values * <0.02 (t-test, n = 3). 
Right panel: Western Blot analysis of EMT markers of the same cells. Molecular weights Mr(K) are indicated in 
kDa. Representative microphotographs of M4 are shown, 200 lm scale bar is indicated. 
 
All together these results indicate that Pin1 is indispensable for breast CSCs maintenance and its 
depletion strongly impairs CSCs number and traits, through the modulation of a specific 
stemness and mesenchymal gene expression program. 
 
5.3 Pin1 promotes breast CSCs maintenance mostly through up-regulation of the Notch 
signalling 
As shown above, breast CSCs depleted of Pin1 display down-modulation of many signalling 
pathways. The majority of these genes are directly -or indirectly- controlled by the Notch 
signalling pathway (Lee et al., 2008; Li et al., 2012; Ranganathan et al., 2011). The role of the 
Notch signalling in breast CSCs and EMT induction is well established, hence we tested if Notch 
is the key mediator of Pin1-mediated stemness. In particular we analyzed the protein levels of 
both Notch1 and Notch4 since their role in breast CSC is well described (Dontu et al., 2004; 
Harrison et al., 2010; Ranganathan et al., 2011). Intriguingly, the levels of their active forms, 
N1-ICD and N4-ICD, were strongly deregulated in Pin1 depleted quaternary (M4) 
mammospheres (Figure 16A). In a previous work we established that that Pin1 potentiates the 
cleavage of the Notch1 receptor, boosting its nuclear levels (Rustighi et al., 2009). However, the 
very strong down-regulation of the Notch nuclear active forms observed in this case could not be 
totally ascribed to a reduced cleavage of the receptor. Since N-ICD levels are finely tuned by 
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proteasomal degradation, we speculated another role for Pin1 in boosting Notch signalling, 
probably through protein stabilization. 
     
Figure 16. N1- and N4-ICD protein levels are decreased in Pin1-silenced mammospheres 
Left panel: Western Blot analysis of N1- and N4-lCD protein from MDA-MB-231-pLKO-shPin1 M4 control cells 
(Ctrl) and shPin1 induced cells (DOX). Molecular weights (Mr) are indicated in kDa. Right panel: histogram 
representing the percentage of band intensity with respect to actin levels. 
 
To understand if the effect of Pin1 on breast CSC required high N1-ICD levels, we tested the 
ability of N1-ICD or of a constitutively stable N1-ICD mutant (dPEST) to boost M2 formation 
following Pin1 knockdown. This mutant lacks the cdc4-phosphodegron (CPD) constituting the 
consensus for the E3 ubiquitin-ligase Fbwx7α. As expected, Pin1 silencing (+DOX) reduced the 
M2FE of MDA-MB-231 pLKO (Figure 16B). Moreover ectopic expression of N1-ICD in 
control cells did not affect the formation of mammospheres, since in these cells the endogenous 
Notch pathway is already strongly activated (Harrison et al, 2010). Interestingly, N1-ICD 
overexpression was not able to rescue M2FE in Pin1 silenced cells. This evidence suggests that 
in this context the role of Pin1 in boosting the Notch cleavage seems to be dispensable, since the 
ectopically expressed N1-ICD is already cleaved and activated. Instead, overexpression of N1-
ICD-dPEST was able to rescue M2FE. When we analyzed the protein levels of Notch nuclear 
active forms we found that protein levels of over-expressed N1-ICD, but not those of N1-ICD-
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dPEST, were strongly decreased in Pin1 depleted mammospheres. 
These data suggest that Pin1 critically supports breast CSC self-renewal by sustaining high 
intracellular levels of N1-ICD. To better address this point, we analysed the endogenous levels 
of both Pin1 and N1-ICD in breast CSCs. Indeed we sorted the Aldh-positive cells from MDA-
MB-231 mammospheres or collected patient derived mammospheres and analysed their protein 
content. As shown in Figure 13, Pin1 and N1-ICD protein levels were always higher in the stem 
cell compartment compared to their differentiated counterpart. Moreover we found that also in 
vivo, in breast cancer tissues, the expression of Pin1 co-localized with Aldh-positive cells 
(Figure 17, right panel). 
 
                 
 
Figure 17. Pin1 and N1-ICD are up-regulated in the CSC compartment. 
Left panel: Comparative Western blot analyses of Aldh-positive (stem) versus Aldh-negative cells (nonstem) sorted 
from MDA-MB-231 M2 (left panel) and patient-derived breast cancer secondary M2 mammospheres (stem) versus 
cells cultured in adherence (2D) (right panel). Relative fold changes in Pin1 or N1-ICD protein levels were 
determined by Image J software with respect to actin levels is indicated by a number. 
Right panel: Representative bright field microphotographs at 100X magnification of immunohistochemical analyses 
of serial sections of a breast cancer with the indicated antibodies are shown. Part of the figure indicated with a 
square is shown by an inset at 400X magnification. Scale bar is indicated. 
 
Over-expression of Pin1 is detected in breast cancers and it is known that ectopic over-
expression of Pin1 is able to disrupt cellular polarity of breast epithelial cells (Ryo et al., 2002), 
but it was not investigated yet if Pin1 is able to promote both an EMT program and formation of 
secondary mammospheres in normal cells and if the Notch signalling is required for this aspect. 
To answer to these questions, we ectopically over-expressed Pin1 in epithelial non transformed 
MCF10A cells and observed that Pin1 promoted an enrichment of the stem cell population, as 
assessed by the specific CD44high/CD24low immunophenotype (Al-Hajj et al, 2003). Moreover 
Pin1 overexpression triggered a huge formation of mammospheres and a concomitant EMT as 
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demonstrated by down- and up-regulation of the two markers E-cadherin and Slug, respectively 
(Figure 18). Crucially, the levels of cleaved Notch1 and Notch4, normally undetectable in these 
cells, were up-regulated by Pin1 over-expression and were essential for mammosphere 
formation, since block of Notch cleavage by a gamma-secretase inhibitor (GSI) was sufficient to 
blunt this process and to reduce the EMT markers as depicted in Figure 18A. 
 
 
Figure 18. Pin1 over-expression promotes an EMT-stem cells phenotype mostly though the Notch pathway. 
A) Upper panel: %M2FE of MCF10A breast epithelial cells transduced with empty (pLPC) or HA-Pin1 
overexpressing vectors (pLPC-HA-Pin1) and treated with DMSO () or 10 lM GSI. Means, standard deviations and 
P-values (t-test, n = 3) are indicated. Middle panel: Representative microphotographs of M2 are shown, scale bar of 
200 lm is indicated. Lower panel: Western Blot of cell lysates from corresponding MCF10A clones. White and 
black arrows indicate over-expressed and endogenous Pin1, respectively. Comparative Western blot analyses of 
Aldh-positive (stem) versus Aldh-negative cells (nonstem) sorted from MDA-MB-231 M2 (left panel) and patient-
derived breast cancer secondary M2 mammospheres (stem) versus cells cultured in adherence (2D) (right panel). 
Relative fold changes in Pin1 or N1-ICD protein levels were determined by Image J software with respect to actin 
levels is indicated by a number.  
B) CD44/CD24 FACS analyses of MCF10A cells transduced with pLPC or pLPC-HA-Pin1. Percentage of the 
different CD44/CD24 populations is indicated on the right. 
 
All together our results demonstrate that Pin1 is a bona fide stem cell factor by promoting EMT, 
maintaining a mesenchymal/stem cell fate and self-renewal of CSCs mainly through regulation 





5.4 Suppression of Pin1 sensitizes breast CSCs to chemotherapy in vitro and in vivo 
There is increasing evidence that, while chemotherapy reduces the tumour mass by killing the 
sensitive cancer cells, it selects a subpopulation of cancer cells that are intrinsically 
chemoresistant or alternatively, it induces cells to acquire resistance to chemotherapy by genetic 
or epigenetic alterations (Dean et al., 2005). In accordance, it has been demonstrated that 
chemotherapy selects and strongly increases the breast CSCs population (Yu et al., 2007). We 
also found that uninduced MDA-MB-231-pLKO-shPin1 cells treated with different 
chemotherapeutic agents display a slight increase in MFE (Figure 19). Instead, when we induced 
Pin1 silencing with doxycyclin (+DOX), this effect was completely lost, since Pin1 depletion 
does not only prevent accumulation of CSC following chemotherapy but more importantly it 
regains chemosensitivity. 
 
Figure 19. Pin1 depletion sensitizes CSCs to chemotherapeutic agents 
Pin1 knockdown synergizes with chemotherapy treatment to block breast CSCs’ self-renewal. Percentage of M2FE 
of control MDA-MB-231-pLKO-shPin1 cells (Ctrl) compared to shPin1-induced cells (DOX) treated with indicated 
drugs or PBS. Means and standard deviations are indicated, P-values are * = 0.001, **< 0.0003 (t-test, n = 3). 
 
To address the in vivo impact of these findings, we performed a xenograft experiment in 
immunocompromised mice by injecting MDA-MB-231 infected with a control- or a Pin1 
shRNA. We allowed the tumour to grow till tumour mass became visible, then mice where 
randomized in different groups and treated with paclitaxel or PBS. When we analyzed the size of 
the tumours, either the treatment with paclitaxel or the silencing of Pin1 similarly reduced the 
tumour mass, while the combination had a strong synergistic effect (Figure 20A). Analysis of the 
cancer stem cells’ content by evaluating the activity of the Aldh enzyme evidenced that, while 
paclitaxel treatment alone reduced the tumour mass but heavily increased the CSC content, the 
concomitant Pin1 depletion prevented this effect (Figure 20B). As a result, Pin1 ablation on one 
hand is able to reduce the tumour mass and the CSCs content, on the other hand it re-sensitize 
CSC to chemotherapy. At the protein level, Western Blot analysis unveiled mesemchymal-to-
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epithelial transition in Pin1 depleted tumours as emerged by the reduction in Slug and Vimentin 
and the concomitant increase in E-cadherin (Figure 20C). Accordingly, N1-ICD levels were 
down-regulated in Pin1 silenced tumours. Moreover the increased cleavage of caspase-3, an 
apoptotic marker, was significantly increased in Pin1-silenced tumours treated with paclitaxel 
underlining a synergistic effect between paclitaxel treatment and Pin1 ablation in inducing 
apoptosis. It has been demonstrated by another group that Pin1 depletion curbed Mcl-1 protein 
levels and promoted apoptosis in breast cancer cell lines treated with paclitaxel (Ding et al., 
2008). To verify the impact of Mcl-1 in our condition, we analyzed its protein levels in our 
xenografts. As expected Mcl-1 levels decreased in Pin1 depleted tumours, but also in the 
paclitaxel treated one, suggesting that Mcl-1 is not directly involved in the CSC accumulation 
due to paclitaxel treatment. More importantly Mcl-1 levels did not further decrease in Pin1 
silenced tumours treated with the drug, suggesting the involvement of another signalling 
pathway that, once inactivated, could give rise to the apoptotic process (Figure 20C).  
 
Figure 20. Pin1 depletion sensitizes CSCs to chemotherapeutic agents in vivo 
A) Pin1 knockdown synergizes with paclitaxel to block breast cancer growth. Tumor growth of MDA-MB-231 
xenografts espressing the indicated shRNAs and treated with paclitaxel (grey bars) or left untreated (PBS) (black 
bars). Means and standard deviations are indicated, P-values are *** < 0.0003 (t-test, n = 12). B) Pin1 knockdown 
blocks chemotherapy-induced breast CSCs’ expansion in vivo. Histogram representing the Aldefluor mean 
fluorescent intensity (MFI) of cells from control- and shPin1 MDA-MB-231 xenografts treated with Paclitaxel or 
PBS. Means and standard deviations are indicated, P-values are * = 0.001 (t-test, n = 3 for each condition). C) Pin1 
knockdown induces reversal of EMT and cell death in breast cancer xenografts in combination with paclitaxel. 
Western blot analyses of tumor xenografts from A). 
 
Indeed, to verify if Notch was the involved signalling pathway, we performed mammosphere 
formation assays with MDA-MB-231 expressing control- or Pin1-specific shRNA and treated 
with paclitaxel. Notably, over-expression of N1-ICD-dPEST totally rescued mammospheres’ 
formation and chemoresistance (Figure 21). 
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All together these data demonstrate that Pin1 is required for the accumulation of chemoresistant 
breast CSCs during chemotherapy and that ablation of its levels or activity curbes the CSCs 
population with concomitant gain of chemosensitivity.  
 
 
Figure 21. N1-ICDs-dPEST over-expression is able to rescue the chemoresistance in Pin1-depleted breast 
cancer cells. 
Left: expression of stable N1-ICD-dPEST rescues resistance to paclitaxel treatment in Pin1 silenced cells. 
Percentage of M2FE of control (black bars) or Pin1 shRNA (grey bars) expressing MDA-MB-231 cells transduced 
with empty (-) or N1-ICD-dPEST (+) expressing vectors and treated with Paclitaxel (+) or PBS (-). Means and 
standard deviations are indicated, P-values are **0.0001, ***<0.00003 (t-test, n = 3). Right: the corresponding 
analysis of protein expression by Western blot is shown. Arrow indicates position of the specific band. 
  
 
5.5 Pin1 protects N1- and N4-ICD from proteasomal degradation 
All the data presented above indicate that N1-ICD protein levels are under direct control of the 
polyl-isomerase, moreover the stable mutant N-ICD-dPEST is unaffected by modulation of Pin1 
levels, suggesting that Pin1 is impinging on N1-ICD turnover through regulation of its protein 
degradation. To test this possibility, we performed protein stability assays. As shown in Figure 
22A, Pin1 depletion by siRNA in MDA-MB- 231 breast cancer cells treated with gamma-
secretase inhibitor to block Notch cleavage at the membrane (Rustighi et al, 2009), reduced the 
half-life of N1-ICD. Addition of the proteasome inhibitor Lacatacystin rescued N1-ICD levels in 
this context, unveiling that this reduced half-life was proteasome-dependent. Pin1 silencing 
curbed the half-life of over-expressed N1-ICD protein also in the SK-BR-3 breast cancer cell 
line that was strongly reduced from 2 h to 40 min upon Pin1 siRNA treatment with respect to 
control silencing (Figure 22B). Moreover, re-introduction of a siRNA resistant Pin1 construct 
(Pin1r) in Pin1 silenced cells prevented the reduction of N1-ICD protein levels, demonstrating 





Figure 22. Pin1 depletion impaired N1-ICD protein half-life 
A) Pin1 knockdown accelerates the decay of endogenous N1-ICD. Western blot of endogenous N1-ICD following 
RNA interference (RNAi) with the indicated siRNAs and time points following GSI or GSI plus Lactacystin (+) 
chase is shown. B) Left panel: Western blot of over-expressed N1-ICD-myc along with indicated siRNAs and 
empty (-) or siPin1 resistant pCDNA3-HA-Pin1 (Pin1r) expression vectors, treated with DMSO (-) or CHX. Right 
panel: Graph indicating N1-ICD-myc protein levels versus time of CHX treatment in the three tested conditions 
(siCtrl, siPin1 and siPin1 + HA-Pin1r). Means, standard deviations and p-values (t-test, n=3) are indicated.  
 
Pin1 is known to bind several substrates on phosphorylated Ser/Thr-Pro residues and to affect 
their stability (Liou et al, 2011). In vitro and in vivo binding assay demonstrated that Pin1 binds 
to N1-ICD and this interaction was direct. Moreover, domain-mapping analysis showed a 
marked reduction in Pin1 binding to N1-ICD when the C-terminal PEST domain containing the 
cdc4-phosphodegron was deleted (Figure 23A). Intriguingly, the residues T2512/P2513 within 
the phosphodegron in the PEST domain are known to be indispensable for recognition by the 
ubiquitin-ligase Fbwx7α when phoshorylated on T2512. To verify if this motif is also a Pin1 
binding site, we performed in vitro GST-Pin1 binding assays with N1-ICD or a mutant construct 
in which we replaced the threonine residue 2512 with alanine (T2512A) (Figure 23B). This 
mutation impaired the interaction between Pin1 and N1-ICD. Accordingly, Pin1 overexpression 






Figure 23. N1-ICD-T2512A mutation hampers binding to Pin1  
A) Mapping of the Pin1-N1-ICD interaction. Upper: Schematic of pCDNA3-N1-ICD-myc C-terminal deletion 
constructs (from d2444 to d1991) used for mapping Pin1 binding domains in N1-ICD. TM: transmembrane, RAM: 
CSL interacting, ANK: ankyrin, STR: Serine-Threonine rich, TAD: transactivation, PEST: Pest domain. Numbering 
refers to Swissprot entry P46531. Interaction with Pin1 is indicated next to the constructs: +++ very strong, ++ 
strong, – no binding. A relevant drop in binding strength is observed by deletion of the PEST domain and the STR. 
Lower: Representative anti-myc tag Western blot analyses of GST-Pin1 pull down assays of indicated proteins 
overexpressed in HEK 293T cells is shown. The borders around the panels demarcate juxtaposed parts of same or 
different gels aligned in function of the molecular weight.. B) Anti-myc tag Western blot analysis of GST-Pin1 or 
GST pull down assay and input levels of indicated proteins overexpressed in HEK 293T cells is shown. (F) N1-
ICD-T2512A mutant half-life is unaffected by Pin1 levels.  C) Western blot of CHX chase experiment with N1-
ICD-myc and N1-ICD-T2512A-myc mutant with empty (-) or HA-Pin1 expressing vectors. Molecular weights 





Finally, these results suggest that the T2512/P2513 motif, indispensable for Fbwx7α recognition, 
constitutes also the docking site for Pin1, which might exert N1-ICD stabilization by interfering 
with Fbwx7α-binding. 
 
5.6 Pin1 protects N1- and N4-ICDs from degradation by the ubiquitin-ligase Fbwx7α 
To test if Pin1 was counteracting N1-ICD degradation by hampering the interaction with the E3-
ubiquitin-ligase Fbwx7α, we tested if Pin1 is able to affect N1-ICD ubiquitination. For this aim 
we performed an ubiquitination assay in COS-7 cells by a Ni-NTA pull down and, as expected, 
over-expression of Fbwx7α in N1-ICD transfected cells, caused an increase in N1-ICD poly-
ubiquitination (Figure 24A). More importantly, when we depleted Pin1 from these cells by 
RNA-interference, we found an enhanced N1-ICD poly-ubiquitination. Thus, Pin1 interferes 
with Fbwx7α-mediated ubiquitination of N1-ICD. Accordingly when N1-ICD and Fbwx7α were 
co-ovexpressed in two different cellular contexts, the concomitant Pin1 over-expression 
completely rescued N1-ICD protein levels (Figure 24B-C). Since the final read-out of Notch 
pathway activation is the transcription of its target genes, we evaluated if Pin1 was able to boost 
Notch dependent transcriptional activity despite presence of high-levels of its negative regulator 
Fbwx7α. Interestingly, as emerged from luciferase assays, Pin1 fully rescued the ability of N1-
ICD to promote gene transcription despite presence of its ubiquitin ligase (Figure 24D). These 
data clearly show that Pin1 is able to prevent Fbwx7α dependent degradation of N1-ICD, 






Figure 24. Pin1 protects N1-ICD from Fbwx7α dependet degradation 
A) Pin1 depletion enhances Fbwx7α-dependent poly-ubiquitination of N1-ICD. Western blot analysis of high 
molecular weight N1-ICD-myc products (N1-ICD-myc) from a Ni-NTA pull-down in COS-7 cells transfected with 
the indicated vectors along with control- or Pin1 siRNA. Input levels of over-expressed proteins are shown. B) Pin1-
/-MEFs transfected with pCDNA3-N1-ICD-myc and increasing amounts of p3xFLAG-Fbwx7α along with either 
empty vector (-) or pCDNA3-HA-Pin1. Borders around the panels demarcate juxtaposed parts of the same gel. C) 
Pin1 overexpression rescues N1-ICD levels in presence of Fbwx7α. Western blot analysis of lysates from SK-BR-3 
cells over-expressing N1-ICD-myc, Flag-Fbwx7α along with empty (-) or increasing amounts of HA-Pin1 
expressing vector, normalized for co-expressed GFP protein. D) Histogram of Luciferase reporter assays in SK-BR-
3 cells co-transfected with pGL2-RBPjκ/LUC and empty vector (-) or pCDNA3-N1-ICD-myc, along with 
p3xFLAG-Fbwx7 and increasing amounts of pCDNA3-HA-Pin1 as indicated by a wedge. Means, standard 
















Figure 16A showed that in Pin1 depleted mammospheres there is a strong decay also in N4-ICD 
levels. Since it has been demonstrated that also N4-ICD is a target of Fbwx7α (Wu et al., 2001), 
we speculated that also in this case Pin1 was able to prevent N4-ICD protein degradation. 
Interestingly, Pin1 silencing in SK-BR-3 strongly increased N4-ICD proteasome dependent 
degradation (Figure 25A) and, accordingly, Pin1 overexpression rescued both N4-ICD protein 
levels and transcriptional activity in presence of Fbwx7α as depicted in Figure 25B.  
 
 
Figure 25.  Pin1 protects N4-ICD from Fbwx7α dependet degradation 
A) Western blot of a CHX chase in SK-BR-3 cells transfected with pCDNA4-N4-ICD-HA along with the indicated 
RNAi, in presence (+) or absence of proteasome inhibitor Lactacystin. B) Histogram of Luciferase reporter assays in 
SK-BR-3 cells co-transfected with pGL2-RBPjκ/LUC and pCDNA4-N4-ICD-HA alone or with p3xFlag-Fbxw7α 
and increasing amounts of pCDNA3-HA-Pin1. Means, standard deviations and p-value (t-test) are indicated for 
three independent experiments. Cell lysates were analyzed by Western blot and are shown below the histograms.  
 
 
To confirm and to strengthen these evidences in vivo, we analyzed N1- and N4-ICD protein 
levels in the epithelial cells of the mammary gland from Pin1+/+ and Pin1-/- mice. As shown in 
Figure 26, from the immunoistochemical and Western Blot analyses performed in Pin1-/- mice it 
emerged that the Notch pathway is strongly reduced, while the levels of Fbwx7α seemed not to 





Figure 26. Pin1-/- mammary epithelial cells display reduced N1- and N4-ICDs protein levels  
A) Microscope images at 400X magnification of sectioned mammary glands from 8 weeks old mice stained with the 
indicated antibodies by immunohistochemistry and counterstained with haematoxylin. Stainings were performed 
without primary antibody (only secondary, IIary Ab) for specificity and with anti-Pin1 antibody as genotype control, 
respectively. Scale bar is indicated. B) Western blot analyses of primary MECs from indicated female mice. 
Molecular weights Mr(K) are indicated in KDa.  
 
 
All these experiments clearly show that Pin1 protects the nuclear active forms of both Notch1 
and Notch4 from the major nuclear ubiquitin-ligase Fbwx7α, boosting their protein levels and 
transcriptional activity. 
 
5.7 Pin1 protects N1- and N4-ICDs from interaction with Fbwx7α 
Pin1 induces prolyl-isomerisation and conformational changes on its targets (Lu et al., 2002a). 
Thus we analyzed if Pin1 is able to disrupt the interaction between Fbwx7α with NICDs. For this 
aim we performed co-immunoprecipitation (Co-IP) experiments with both endogenous and over-
expressed NICDs and Fbwx7α.  
Co-IP in MDA-MB-231 unveiled that the binding between N1- and N4-ICD with Fbwx7α is 
increased when Pin1 activity was blocked with PiB (Figure 27A). Accordingly, we recapitulated 
these results in another cell line by over-expressing N1-ICDs and Fbwx7α following control- or 
Pin1-silencing (Figure 27B). Similar experiments performed in Pin1-/- fibroblasts unveiled that 
the catalytic activity of Pin1 was required for this effect. Indeed while over-expression of Pin1 is 
able to prevent the binding between N1-ICD and Fbwx7α, the catalytic inactive mutant Pin1S67E 





Figure 27. Pin1 prevents the interaction between N1/N4-ICDs and Fbwx7α 
A) Inhibition of Pin1 increases interaction between endogenous Fbwx7α and N1-ICD proteins. Western blot 
analysis of co-immunoprecipitation (Co-IP) experiments between endogenous Fbwx7α and both N1-ICD and N4-
ICD from MDA-MB-231 cells treated with DMSO (-) or PiB (+). Anti-Fbwx7α or non-related antibody (NRA) 
immunoprecipitates (IP) were recognized with anti-N1-ICD (Val1744) and anti-N4-ICD (Val1432) antibody and 
after stripping with an anti-Fbwx7α antibody. Input levels are shown below.	   B) Left Panel: depletion of Pin1 
increases Fbwx7α-N1-ICD interaction. Representative Western blot analysis of Co-IP experiments between over-
expressed N1-ICD-myc and Flag-Fbwx7α in SK-BR-3 cells. Over-expressed N1-ICD-myc was immunoprecipitated 
(IP) and subjected to anti-Flag Western Blot to reveal Flag-Fbwx7α Co-IP. Input levels of over-expressed or 
silenced proteins are shown below. Right Panel: Graph depicting the mean of Flag-Fbwx7α Co-IP levels, 
normalized to immunoprecipitated N1-ICD. Standard deviations and p-value (t-test, n=3) are shown. C) Pin1 
catalytic activity is required to uncouple N1-ICD from Fbwx7α. Co-IP as in (B) in Pin1-/- embryo fibroblasts 
transduced with the indicated vectors. A)-C) Molecular weights Mr(K) are indicated in KDa.	  
 
 
All these data demonstrated that Pin1 is boosting Notch1/4 nuclear levels by impairing 





Figure 28. PP2A is required for the Pin1-dependet N1-ICD detachment from Fbwx7α . 
A) Inhibition of PP2A enforces Fbxw7a-N1-ICD interaction. Co-IP as above in figure 24 SK-BR-3 cells treated 
with DMSO (-) or okadaic acid and transduced with the indicated vectors. B) Inhibition of PP2A accelerates the 
half-life of endogenous N1-ICD. Western blot analysis of a GSI chase of MDA-MB-231 cells treated with vehicle 
(DMSO) or okadaic acid. Anti-p21Cip1Waf1 immunoblot was added as control for Okadaic acid functioning (Park 
et al, 2001). C) PP2A is required for Pin1-dependent N1-ICD detachment from Fbxw7a. Co-IP as above in SK-BR-
3 cells transduced with the indicated vectors and treated with DMSO (-) or okadaic acid. 
 
Moreover we wanted to uncover the mechanism by which Pin1 is protecting N1/4-ICDs from 
Fbxw7α. It is known that prolyl-isomerization of specific phospho-S/T-P sites leads, on certain 
substrates, to recognition and subsequent dephosphorylation by the trans-specific phosphatase 
PP2A (Liou et al, 2011). Insights from a nuclear Notch1 interactome revealed that PP2A binds to 
N1-ICD (Yatim et al., 2012). Hence, we investigated if, following isomerization by Pin1, the 
Notch cdc4-phosphodegron could be dephosphorylated by PP2A, thus eluding recognition by 
Fbxw7α. To evaluate this possibility we performed co-imunoprecipitation assay between N1-
ICD and Fbxw7α in SK-BR-3 cells treated with the PP2A inhibitor okadaic acid. Interestingly 
the interaction between N1-ICD and Fbxw7α increased when cells were treated with okadaic 
acid (Figure 28A). Accordingly, when we analyzed the protein half-life of N1-ICD in MDA-
Results 
 
MB-231 we found that okadaic treatment enhanced N1-ICD protein dregradation (Figure 28B). 
We next analyzed the dynamics of this interaction following Pin1 overexpression in the same 
conditions as above. As shown in Figure 28C Pin1 expression consistently reduced the 
interaction between N1-ICD and Fbxw7α but only in the presence of functionally active PP2A, 
indicating that PP2A is required for Pin1-dependent N1-ICD accumulation. 
 
5.8 Pin1 and Fbwx7α interplay affects Notch-dependent stem cells traits  
Pin1 and Fbwx7α are able to tightly control the Notch signalling pathway at the nuclear level. 
Since the role of both Notch1 and Notch4 in the breast CSCs maintenance is well known, we 
investigated if the Pin1-Fbwx7α interplay on the Notch pathway can affect the CSC population. 
For this aim we performed mammosphere assays with MDA-MB-231 by over-expressing Pin1 
and Fbwx7α. Interestingly Fbwx7α over-expression had a great effect in reducing the 
mammosphere formation, the percentage of putative CSCs as detected by the reduced number of 
Aldh+ cells and also the nuclear levels of both N1- and N4-ICDs and the transcriptional target 
HES1 (Figure 29). This inhibitory effect on the CSC populations mediated by Fbwx7α is almost 
completely abolished by a concomitant over-expression of Pin1 that, through stabilization of 
N1/N4-ICDs, recovered the mammosphere formation ability and the percentage of Aldh+ cells. 
To verify the contribution of the Notch signalling in this context, we treated cells in all the 




Figure 29. Pin1 and Fbwx7 modulate Notch breast CSCs activity in vitro  
A) %M2FE of MDA-MB-231 cells overexpressing the indicated vectors. Black and grey bars indicate DMSO or 
GSI treated mammospheres, respectively. Means, standard deviations and P-values (t-test, n = 3), are indicated.  B) 
Representative microphotographs of M2 are shown, 200 lm scale bar is indicated.  C) Percentage of Aldh positive 
cells of clones from Figure 7A grown as mammospheres, calculated as Median flurescence intensity (MFI) 
difference between samples containing BAAA and that of the same samples containing also DEAB. D) Western 
Blot of cell lysates from M2. White and black arrows indicate over-expressed and endogenous Pin1, respectively. 




Since Fbwx7α acts on several important targets (Wang et al, 2011), we assessed the relevance of 
Notch activity for this phenotype. As shown in Figure 30, down-modulation of Fbwx7α caused a 
consistent increase of N1-ICD levels, boosted M2FE while treatment with GSI elicited a strong 
reduction of both mammosphere formation and Notch pathway activation, thus demonstrating 




Figure 30. Fbwx7 depletion increased mammospheres formation through Notch pathway  
Left panel: Histogram showing %M2FE of MDA-MB-231 cells with the indicated siRNAs and treated with vehicle 
(black bars) or GSI (grey bars). Means, standard deviations and P-values (t-test, n = 3), are indicated. Right panel: 
WesternBlot of cell lysates from M2. Molecular weights (Mr) are indicated in kDa. 
 
We next addressed the Pin1-Fbwx7α interplay in CSCs maintenance in an in vivo experiment by 
testing the tumour initiation properties. In particular, we performed a limiting dilution assay by 
injecting increasingly diluted MDA-MB-231 cells over-expressing Fbwx7α, or Fbwx7α plus 
Pin1, in the inguinal mammary glands of SCID mice. As shown in Table 1, while 300.000 
injected control cells gave rise to a tumour in all mice, Fbwx7α strongly impaired the tumour 
initiating properties, since only 2 out of 9 mice harboured palpable tumours. Notably, 
concomitant Pin1 over-expression significantly rescued the tumour initiation capability in Fbxw7 
over-expressing MDA-MB-231 to 7 out of 9 mice. At the subsequent dilution the same trend 
could be appreciated, demonstrating in vivo a potent counteraction of Pin1 and Fbwx7α in 














Table 1. Mice were transplanted with decreasing numbers of MDA-MB-231 cells overexpressing empty, Fbwx7α, 
or Fbwx7α + Pin1 vectors (number of injected cells is indicated). Results are shown as the number of tumors per 
number of injected mice (upper panel). CSC frequencies (estimates and upper/lower limits) were calculated by 
limiting dilution analysis, as described in Materials and methods. Differences in CSC frequencies are indicated for 
each sample against the empty vector and for Fbwx7α + Pin1 against Fbwx7α only. Their significance is indicated 
by a P value (lower panel). 
 
 1.000.000 600.000 300.000 150.000 
  empty 6/6 9/9 9/9 12/15 
    Fbwx7α 6/6 9/9 2/9 1/15 
  Fbwx7α + Pin1 6/6 7/8 7/9 5/15 
    Estimate (0.95)          (Lower-Upper)           P value      P value 
empty           1:144232       (1:84380-1:49364)   
 Fbwx7α           1:776940     (1:485184-1:302989)         1.58 x 10-6  
 Fbwx7α + Pin1           1:466587     (1:302232-1:195771)         1.04 x 10-2       0.0239 
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The content of CSCs in a tumour is linked to several aggressive features, such as tumour growth 
and metastasis formation. To gauge for these features, we performed xenograft experiments by 
injecting 1.000.000 of cells/flank with the same MDA-MB-231 clones used above. Notably 
Fbwx7α exerted a potent tumour suppressor activity as emerged by the fact that, compared to 
empty vector infected cells, MDA-MB-231 over-expressing Fbxw7α gave rise to small tumour 
with an impaired Notch signalling, a reversal of EMT, and a reduced number of metastases to the 
nearby lymph nodes and to the lungs. By contrast tumours that co-expressed Pin1 and Fbwx7α 
were growing faster, with a re-activation of the Notch signalling, a rescue of mesenchymal 
markers and dissemination of metastases (Figure 31).  
In summary, we uncovered a potent role of Fbwx7α in reducing the breast CSC traits through a 
down-regulation Notch1/4 activity by promoting degradation of their nuclear active forms. In 
this context, concomitant Pin1 over-expression reverted all these effects boosting N1/4-ICDs 





















Figure 31. Pin1 and Fbwx7α modulate Notch breast CSCs activity in vivo  
A) Tumour volume of orthotopic xenografts in SCID mice obtained from the indicated MDA-MB-231 cell clones. 
B) qRT-PCR of Fbwx7α and Fbwx7α+Pin1 tumor xenografts relative to control tumors (empty) explanted at the end 
of the experiment. C-D) Western blot of Fbwx7α and Fbwx7α + Pin1 tumor xenografts relative to control tumors 
(empty) explanted at the end of the experiment E-F) Representative images of colonized lymph nodes E) and 
hematoxylin and eosin stained pulmonary sections F) are shown. Rulers and Scale bars (1 mm) are indicated for 
calibration, arrows indicate metastatic areas. A), B), E), F) Means, standard errors of the mean and P-values (t-test, n 




5.9 Pin1 sustains Notch signalling in primary breast cancers in spite of Fbxw7a expression 
According to CONAN, Cosmic and TCGA databases and recent publications, FBXW7 and 
NOTCH a rarely mutated in breast cancer (Byrd et al., 2008; Ibusuki et al., 2011; Mao et al., 
2008; Santarpia et al., 2012), but its known that Notch pathway is over-activated in many breast 
cancers (Farnie et al., 2007; Han et al., 2011; Pece et al., 2004; Reedijk et al., 2005; Rizzo et al., 
2008; Rustighi et al., 2009; Xu et al., 2012). We have discovered a mechanism by which, despite 
absence of mutational events and presence of the ubiquitin-ligase Fbwx7α, N1- and N4-ICD are 
up regulated because of high Pin1 protein levels. 
This hypothesis prompted us to analyze breast cancer tissues from patients to address if our 
mechanism occurs also in human patients. We took 43 breast cancer tissues from which the 
protein levels of N1-ICD had been already detected by IHC (Verzemovic et al., submitted). We 
extracted the total RNA from these tissues and analyzed the mRNA levels of Pin1 and Fbwx7α; 
notably it has been demonstrated that their mRNA levels provide a direct correspondence to 
protein levels. The tissues were grouped, based on the N1-ICD protein levels, into high or low 
expressing (Figure 32). Interestingly, 11/17 tissues displaying high N1-ICD protein levels, 
expressed also high FBXW7α mRNA levels and more importantly all of them expressed high 
PIN1 levels. Moreover while FBXW7α did not correlate with any of the categories, PIN1 levels 
were higher in the high N1-ICD expressing group. This evidence suggests that high N1-ICD 
protein levels can coexist with its negative regulator Fbwx7α because of high Pin1 expression. 
 
Figure 32. Association of FBWX7Α or PIN1 expression in N1-ICD high and low breast cancers 
A) Heatmap representing the expression of PIN1 and FBWX7 (detected at mRNA expression level) and N1-ICD 
(detected at protein level) in a cohort of 43 breast cancer patients. The color in each block represents if the mRNA 
or protein is above (red) or below (blue) the average value of the samples for each gene or was scored high or low 
by immunohistochemistry, respectively B) Left panel: Box-plot representations of gene expression values (of 
FBWX7 and PIN1, upper and lower panels, respectively) in the breast cancer cohort of Figure S8A. Patients were 
binned in low or high categories for weak or strong N1-ICD staining (detected by IHC, see Methods for detail). 
Finally, to test the associations between N1-ICD staining and expression of FBWX7 and PIN1, Wilcoxon rank sum 
tests were performed. The results showed no association for FBWX7 (W = 192, p-value = 0.8998) and very strong 
association for PIN1 (W = 35, p-value = 2.967 x 10-6). Right panel: Contingency table showing percentage of each 
category calculated on the precedent category of patients from A). 
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To strengthen our observation we analyzed another cohort of breast cancer tissue from 38 
patients (Figure 33). We selected in particular tissues of triple negative breast cancer subtypes, 
which have been described to be chemoresistant, highly metastatic and of grade 3, suggesting 
that they are also enriched in CSCs (Pece et al., 2010). We analyzed the protein levels of Pin1, 
N1-ICD ad Fbwx7α by immunohistochemical analysis. We found that 22/38 tissues display high 
N1-ICD nuclear protein levels and in 72.7% of them there was also a strong nuclear 
accumulation of Fbwx7α. Again, a large part of this group presented also high Pin1 protein 
levels as shown in Figure 32.  
 
 
Figure 33. High N1-ICD levels in human breast cancers coexist with Fbwx7α thanks to high Pin1 expression  
Left panel: Heatmap representing the protein levels of Pin1, Fbwx7α and N1-ICD in a cohort of 38 breast cancer 
patients. The colours represent high (red) or low (blue) protein levels according to protein expression scores (see 
supplementary Methods). Right panel: Contingency table showing percentage of each category calculated on the 
precedent category of patients; chi-square test was performed for independence between the variables and the P-
value = 105. 
 
Finally we analyzed a medataset of la arge cohort of 3254 breast cancer patients collected from 
19 independent studies (see Material and Methods). We stratified patients into high or low levels 
of FBXW7α and PIN1 expressing patients (Adorno et al., 2009). Since the Notch mRNA is not a 
representative of N1-ICD protein levels, we generated a signature, that reflects the Notch 
pathway activation, since it is was created by selecting Notch direct transcriptional targets (NDT 
signature) (see Material and Methods). 48% of all samples exhibited high NDT expression and 
correlated with poor overall survival (Figure 34). Notably 51.7% of these samples displayed also 
high FBWX7α mRNA levels and again the majority of this group presented high PIN1 levels.  
Results 
 
                                                                                                 
 
 
     
 




                                                     
 
Figure 34. High N1-ICD levels in human breast cancers coexist with Fbwx7α thanks to high Pin1 expression  
Upper panel: heatmap representing the contingency table frequencies of samples classified as having high or low 
levels of FBWX7Α, of PIN1 and of the NDT gene signature. Number of samples in each category is indicated on 
the left. The association among high levels of NDT gene signature, PIN1, and FBWX7Α resulted statistically 
significant (P < 0.001; chi-square test). Lower panel left: Contingency table showing percentage of each category 
calculated on the precedent category of patients. : Expression correlation between NDT and PIN1 and FBWX7Α 
mRNA levels. Average expression of NDT gene signature in breast cancer samples stratified according to high or 
low expression of PIN1 and FBWX7Α mRNA. Data are shown as mean and standard error of the mean (s.e.m.). 
Lower panel right: Kaplan-Meier graphs representing the probability of survival in 1173 breast cancer patients from 
the meta-dataset of the Upper panel, with outcome information on survival. Tumor samples were classified as high 
or low Notch-dependent Direct Target (NDT) gene signature using the classifier described (Adorno et al., 2009). 
The log-rank test p value reflects the significance of the association between NDT gene signature low and longer 
survival.  
 
In summary, all the 3 analyses confirmed our hypothesis that in breast cancer patients N1-ICD 
could coexist with its ubiquitin-ligase thanks to high Pin1 expression. Moreover the category 
displaying high NDT and Fbwx7α expression but low Pin1 is the less represented compared to 
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any other category. Accordingly, the average expression value of NDT was contingent on Pin1, 
while the Fbwx7α status was not influential, strengthening the idea that Pin1 is dominant, over 
Fbwx7α, in modulating Notch pathway in breast cancers (Figure 34).  
In this work we discovered a functional interaction between Pin1, N1-ICD and N4-ICD in breast 
CSCs and aggressive breast tumour traits. Since all these features are connected to poor clinical 
outcome in patients, we analyzed in our cohort from figure 34 the survival of patients. Notably, 
as shown in Figure 35, we found that in the grade 3 breast cancers of this cohort, high Pin1 
levels correlated with a worse outcome only in patients with activated Notch signalling. By 
contrast, in patients with low Notch signalling, Pin1 is unable to stratify patients, thus indicating 
that Pin1 requires Notch activation to promote aggressiveness and poor clinical outcome.  
 
 
Figure 35. Pin1 levels correlate with poor clinical outcome only in patients with high NDT signature. 
A) Kaplan–Meier survival curve is indicated for high NDT signature, grade 3 breast cancer patients of the 
metadataset in function of high or low PIN1 mRNA levels. P-value and the number of subjects at risk at each time 
point is indicated below. B) Kaplan–Meier survival curve is indicated for low NDT signature, grade 3 breast cancer 
patients of the metadataset in function of high or low PIN1 mRNA levels. P-value and the number of subjects at risk 
at each time point is indicated below. 
 
 
To understand which molecular pathways are over-represented in patients with high Pin1/high 
NDT compared to patients with high Pin1/low NDT, we performed a Gene set enrichment 
analysis. Interestingly, as depicted in Table 2, we found enrichment of several stem cell pathway 
signature genes in this group of patients, supporting our findings of a pro-CSCs program induced 











Table 2. Enrichment of gene signatures in the list of genes preferentially expressed in NDT signature HIGH/PIN1 
HIGH versus NDT signature HIGH/PIN1 LOW tumors in the metadataset (GRADE 3). Differentially expressed 
genes (n=1460, q-value <0.01 and fold change >1.5) were subjected to Gene set enrichment analysis (GSEA) as 
already described (Montagner et al., 2012). Enrichment has been determined using a Fischer’s exact test on all 254 
signaling pathways in the database. P-values have been corrected using BH procedure 
SIGNATURES 
(BIOCARTA PATHWAY + OTHER 
SIGNATURES) 
ENRICHMENT in  













Cancer stem cells represent a major problem for breast cancer treatment, as they are responsible 
for tumour heterogeneity, recurrence, chemoresistance metastatic dissemination. Many studies 
have been carried out to understand the molecular bases of their sustenance, that have led to the 
identification of several involved signalling pathways, transcriptional factors and micro-
environmental stimuli showing that CSCs may take advantage of the normal stem cell molecular 
machinery to maintain their self-renewal. Here we demonstrate that the prolyl-isomerase Pin1 is 
required for both normal and cancer stem cell biology. These Pin1 pro-stemness functions are 
mediated through the maintenance of both N1 and N4-ICD protein levels, protecting them from 
the tumour suppressor and E3-ubiquitin ligase Fbwx7α. Pin1 and Notch signalling promote each 
other since Notch1 directly induces Pin1 transcription(Rustighi et al., 2009). Thus the Pin1-
Notch1/4 axis promotes a pro-CSCs program by up-regulating EMT markers, stemness 
signalling pathways and proteins involved in chemoresistance, regardless of Fbwx7α, as depicted 
by the model in Figure 36. As a consequence, genetic or pharmacological ablation of Pin1 
suppresses CSC number and self-renewal, reduces the number of tumour initiating cells, the 
metastases dissemination and, more importantly, recovers sensitivity to chemotherapy both in 
vitro and in vivo. 
 
Figure 36. Schematic model that depicts the role of Pin1 in sustaining CSCs through Notch1 and Notch4 by 
antagonizing Fbxw7α-mediated destruction. 
 
In G3 breast cancer patients, high Pin1 levels are associated to poor clinical outcome when 
Notch signalling is activated. Therefore, since it has been demonstrated that G3 are enriched in 
CSCs, it is conceivable that a major mechanism by which Pin1 is involved in cancer progression 
might be its promotion of the CSCs number. In addition, Pin1 has not yet been linked to any 
particular subtype or unique mutational event in breast cancer, nevertheless its levels increase in 
parallel with the tumour grade and it cooperates with several oncogenic pathways. In particular it 
cooperates with several oncogenes or oncogene-induced factors, that are involved in almost all 
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the breast cancer subtypes such as estrogen receptor alpha (ERα+) tumors (Rajbhandari et al., 
2012), progesterone receptor (PR) (Yi et al., 2005), Her2/Neu (Wulf et al., 2003), mutp53 
(Girardini et al., 2011) and Notch1/4. Moreover Pin1-/- mice display reduction of the stem cell 
compartment without perturbing the luminal or myoepithelial fate commitment, as suggested by 
an unchanged proportion of the myoepithelial and luminal populations in Pin1-/- mice (Figure 
9). Therefore, it seems that Pin1 goes beyond the heterogeneity of breast cancer, since it 
impinges on the heart of basic oncogenic mechanisms, and it could therefore be an important 
molecular target for breast cancer therapy. Indeed, ablation of Pin1 can reduce the CSCs 
population, the specific subtype driven breast cancer oncogenes and elicit sensitivity to 
chemotherapy. 
 
A role for both Pin1 and Notch pathway in the promotion of chemoresistance has been well 
demonstrated (Ding et al., 2008; Ranganathan et al., 2011). Of note, the role of Pin1 is 
controversial, since on one hand it promotes apoptosis through p53 following genotoxic stress 
(Wulf et al., 2002; Zacchi et al., 2002), on the other it promotes chemoresistance acting on Mcl-1 
stability (Ding et al., 2008). Nevertheless, to date no in vivo experiment has been done to address 
how Pin1 dictates the cellular response to pharmacological treatments. Here we provide a clear 
demonstration of the pro-survival role of Pin1 in presence of chemotherapy in breast cancers 
with in vitro and in vivo experiments. In particular breast tumour cells and CSCs depleted for 
Pin1 display reduction of the Notch signalling, of the drug efflux pump ABCG2 (Sarkadi et al., 
2006), of the pro-survival factor SURVIVIN (Fukuda and Pelus, 2006), of the detoxification 
enzyme Aldh (Ginestier et al., 2009), and other factors for which a role in chemoresistance is 
already known. This evidence coupled with the fact Pin1 promotes exhaustion of CSC, point out 
Pin1 as an important mediator of chemoresistance in breast cancers through many mechanisms. 
Notch1 and Notch4 receptors have been linked to many diseases such as cancer (Ranganathan et 
al., 2011). Notch1 has been associated for the first time to tumourigenesis in human T-cell acute 
lymphoblastic leukemia (T-ALL) due to mutational events that unleash high levels of N1-ICD in 
tumour cells and, accordingly, in 50% of T-ALL there are mutational events on NOTCH1 or 
FBXW7α (Ferrando, 2009). Moreover, in leukemia cells, high levels of Notch signalling are 
important for the CSCs maintenance (Liu et al., 2013). Intriguingly Notch proteins are also over-
activated in breast cancer and important for normal and cancer stem cells; while Notch1 seems to 
be more important for luminal progenitors, Notch4 seems to be more related to bipotent stem 
cells (Dontu et al., 2004; Harrison et al., 2010; Raouf et al., 2008). Despite the high percentage 
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of mutational events in T-ALL, in breast cancer there are rare mutations on FBXW7α and 
NOTCH1 which can not provide molecular explanation for the great percentage of mammary 
tumours displaying high levels of N1/4-ICD protein levels. Our findings unveil a mechanism by 
which Pin1 is responsible for elevated Notch signalling in breast cancers without the need of 
mutational events on NOTCH and FBXW7α. Thus, an over-activated Notch-Pin1 axis can 
promote normal and cancer stem cells despite high levels of functional Fbwx7α. 
 
New insights for the tumour suppressor Fbxw7α  in breast cancer 
There is only limited evidence in the literature that links Fbxw7 to breast tumours. Nevertheless 
this ubiquitin-ligase is a potent tumour suppressor in many other tumours. Overall, 
approximately 6% of tumours harbour mutations in FBW7, but there is substantial variation 
among tumour types. The highest mutation rates (approximately 30%) were found in 
cholangiocarcinoma and T‑cell acute lymphoblastic leukaemias (T-ALL) whereas 
gastrointestinal cancers (pancreatic and gastric) as well as prostate and endometrial cancers had 
mutation frequencies in the range of 4–15% (Welcker and Clurman, 2008). By contrast, many 
tumour types do not exhibit or only rarely exhibit mutations in FBW7, in particular breast 
cancers. Rather, very often the oncogenic substrate proteins of Fbxw7, such as c-Myc or Notch1, 
have the CPD mutated in order to escape Fbxw7-mediated recognition and proteasomal 
degradation. 
In tumours with low mutations on Fbxw7 gene, deregulation of its protein levels is not 
documented and the role of Fbw7α inactivation by dominant oncogenes in human tumours is not 
known, with exception of human colon cancers where Fbxw7α protein levels were found 
decreased due to high levels of Pin1 (Min et al., 2012). By our observations in mice and human 
breast cancer samples, we did not find any correlation between Fbxw7α and Pin1 levels. 
Notably, and unexpectedly, also N1-ICD nuclear levels did not correlate with those of its 
ubiquitin-ligase Fbxw7. Notwithstanding, there might be a proportion of breast cancer patients 
where Pin1 and Fbxw7 are inversely correlated due to inactivation of Fbxw7 by Pin1, suggesting 
a further level of cooperation between Pin1 and several oncogenes in cancer. Here, we have 
described that a quite high number of breast cancer patients have high N1-ICD levels despite 
high levels of Fbxw7, due to the concomitant presence of Pin1 that protects N1/4-ICDS from 
degradation. Ablation of Pin1 allowed Fbxw7 to interact with and turn-off the Notch pathway 
strongly impacting on tumourigenesis. Indeed in vitro and in vivo experiments demonstrated that 
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Fbxw7α over-expression strongly impaired the number and the self-renewal of breast CSCs, 
curbed tumourigenesis formation and metastases dissemination. Interestingly Fbxw7α controls 
the number and maintenance of stem cells in many other cells such as neurons, colon and 
hematopoietic cells mostly through regulation of the Notch signalling (Wang et al., 2012). It will 
be interesting to investigate if, in absence of mutational events on NOTCH or FBXW7 genes, 
also in these tissues Pin1 could cooperate with the Notch signalling pathways in the maintenance 
of normal and cancer stem cells. 
 
The interplay of the Notch-Pin1 axis with other signalling pathways 
The interplay between Pin1 and N1-ICD is not simply restricted to NICDs protein stabilization 
and Pin1-induced transcription. Indeed the Notch pathway is highly inter-connetected with 
several signalling pathways such as PI3K/Akt, Jak/STAT, NF-kappaB, ErbB2, Wnt, and HIF1 
(Ranganathan et al, 2011). Strikingly, considering that most of them are also Pin1 substrates 
(Kim et al, 2008; Liou et al, 2011), this isomerase may contribute to increase Notch induced 
oncogenesis also by amplifying the signalling emerging from these cross-talks. In addition, the 
death associated protein kinase 1 (DAPK1), a tumour suppressor that negatively controls Pin1 
activity (Lee et al., 2011), was shown to be repressed by N1-ICD (Li et al., 2008), suggesting 
that Notch signalling is not only boosting Pin1 transcription but also its activity. 
Another important interactor of both Notch signalling and Pin1, is the tumour suppressor p53 
(Beverly et al., 2005; Kim et al., 2007; Sun et al., 2011; Wulf et al., 2002; Zacchi et al., 2002). 
Interestingly wild-type p53 (wtp53) has a fundamental role in the regulation of the breast stem 
cell compartment, since its depletion leads to an uncontrolled symmetric expansion boosting the 
number of stem cells (Bonizzi et al., 2012; Cicalese et al., 2009; Insinga et al., 2013). Notably, 
pharmacologic inhibition of the Notch signalling in p53 depleted CSCs is able to revert the 
phenotype with a consequent reduction of CSCs number (Tao et al., 2011). The role of wtp53 in 
our findings is not evident, raising the question on whether in the mammary stem cell 
compartment Pin1 could act by modulating p53 and Notch functions in concert, unveiling novel 
intersections between these two pathways. While in vitro the activity of Pin1 on p53 has been 
well characterized in the context of genotoxic stress signalling acting on the wtp53, their 
interplay in the stem cell compartment remains to be elucidated. The fact that Pin1-/- mice have 
reduced mammary stem cells (Figures 1 and 2), in contrast with what has been observed in the 
TP53-/- genotype (Bonizzi et al., 2012; Cicalese et al., 2009), allows speculating a more complex 
scenario for a wtp53-Pin1 interplay in these cells. 
Discussion 
 
On the other hand, also for oncogenic gain of function (GOF) mutant p53 proteins, there is 
growing evidence that supports a role in promoting cellular reprogramming and EMT and 
inciting expansion of mammary epithelial stem cells giving rise to mammary tumours (Chang et 
al., 2011; Dong et al., 2013; Lu et al., 2013b; Sarig et al., 2010). Nevertheless no in vivo 
experiment has been done yet to understand the molecular processes controlled by mutp53 in 
breast stem cells. In this context, we have recently demonstrated a key role of Pin1 in promoting 
mutp53 GOF in breast cancer (Girardini et al., 2011). On these bases, it is conceivable that in 
CSCs lacking wtp53 or expressing oncogenic mutp53, increased levels of Pin1, due to a 
hyperactivated Notch pathway, may foster stem cell traits by acting both on mutp53 oncogenic 
properties and on Notch itself. In support of this hypothesis, our analysis revealed that poorly 
differentiated grade 3 and NDT-high/PIN1-high breast cancers are enriched for the expression of 
stem cell and mutp53 signature genes. 
 
In conclusion, this study has two major impacts. First, our findings provide explanation to 
understand how, in the absence of mutations in NOTCH genes, in a consistent proportion of 
breast cancer patients, activated Notch1 can exist in spite of the presence of its major constrain, 
the tumour suppressor Fbxw7α. The data presented, in fact, suggest that deregulated activity of 
Pin1, at least in breast cancer, where mutational events in NOTCH1 and FBXW7 are rare, could 
reduce the selective pressure for mutations providing an alternative mechanism for Notch 
oncogenic activation. 
Second, our findings pinpoint Pin1 as a crucial target in aggressive breast cancers, providing the 
rational for a therapeutic strategy based on Pin1 inhibition to hit CSCs, restore chemo-
sensitiveness and inhibit metastatic spread.  
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7. MATERIAL AND METHODS 
 
Cell lines and treatments.  
MDA-MB-231, SK-BR-3, BT-549, and SUM-159 are human breast carcinoma cells, HEK 293T is a 
human embryonic kidney cell line with SV40 large T, immortalized Pin1-/- fibroblasts have been obtained 
by spontaneous immortalization from Mouse Embryo Fibroblasts of C57BL6/129Sv mixed background 
(Rustighi et al., 2009). COS-7 are monkey kidney cells immortalized with SV40 large T antigen. NOP6 is 
a mouse mammary tumor cell line (Yang et al., 2009). All cells were cultured in DMEM, supplemented 
with 10% Fetal Bovine Serum (Gibco) and Penicillin/Streptomycin, as described (Rustighi et al., 2009). 
For NOP6, in addition Insulin supplements were added (Yang et al., 2009). MCF10A cells were 
maintained in DMEM:F12 Ham’s (1:2; Sigma), supplemented with 5% horse serum (Gibco), insulin (10 
µg ml–1; Sigma), hydrocortisone (0.5 µg ml–1) and EGF (20 ng ml–1; Peprotech). Primary breast cancer 
cell lines were maintained in F12 Ham’s supplemented with 10% FCS and insulin, hydrocortisone and 
EGF as above. Transient transfections, retroviral or lentiviral infections were performed by standard 
procedures, as described (Rustighi et al., 2009). pEGFP was included as control for transfection 
efficiency. For creation of stable clones, a selection corresponding to the expressed vectors was applied 
for 2 weeks to infected cells at the concentrations of 2 µgr/ml for Puromycin and 0,5mg/ml for 
Blasticidin. Cycloheximide (Sigma) for chase experiments was used at 50 nM concentration. Treatment 
with gamma-secretase inhibitor DAPT (Sigma), Pin1 inhibitor PiB (Calbiochem) or proteasome inhibitor 
lactacystin (Sigma) have been described previously (Rustighi et al., 2009). Protein phosphatase inhibitor 
Okadaic Acid (Sigma) was dissolved in DMSO and used at a final concentration of 200 nM for 6h. 
 
Isolation and purification of mammary epithelial cells. 
Mammary glands from 8 to 12-week-old virgin female mice were enzymatically digested and single cell 
suspensions of purified mammary epithelial cells were obtained, as described (Sleeman et al, 2006; Stingl 
et al, 2006). Briefly, Mammary glands from 8 to 12-week-old virgin female mice were digested for 1–2 h 
at 37°C in Epi-Cult-B medium (StemCell Technologies Inc, Vancouver, Canada) with 600 U/ml 
collagenase (Sigma-Aldrich, St. Louis, MO, USA) and 200 U/ml hyaluronidase (Sigma). After lysis of 
the red blood cells with NH4Cl, the remaining cells were washed with PBS/0.02% w/v EDTA to allow 
cell-cell contacts begin to break down. Cells were then dissociated with 2 ml trypsin 0.25%w/v, 0.2% w/v 
EDTA for 2 min by gentle pipetting, then incubated in 5 mg/ml Dispase II (Sigma) plus 1 lg/ml DNase I 
(Sigma) for 5 min followed by filtration through a 40 lM cell strainer (BD Falcon, San Jose, CA, USA). 
Mammary epithelial cells were then purified using the EasySep Mouse Mammary Stem Cell Enrichment 
Kit (StemCell Technologies Inc). 
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Flow cytometric analyses and sorting (FACS) 
Mouse mammary epithelial lineage-depleted cells, pre-enriched using the EasySep Mouse Mammary 
Stem Cell Enrichment Kit (see above), were analysed by FACS and sorted to near purity (85%) with 
antibodies against CD49f and CD24. FACS analysis and sorting from mammospheres based on aldehyde 
dehydrogenase (Aldh) activity were performed using the Aldefluor kit (StemCell Technologies Inc) 
following the manufacturer’s instructions and are detailed in Supporting Information. Briefly, cells were 
incubated with active substrate (BAAA) in presence or absence of a specific adehyde dehydrogenase 
inhibitor (DEAB) for 30-60 min at 37°C, to allow conversion of BAAA into a fluorescent product 
(BAA). Fluorescence was measured by flow cytometry (FACS Calibur) using adjusted FSC and SSC 
voltages to center the nucleated and viable cell population. DEAB treated vs. non treated cells were used 
to identify Aldefluor positive cells. Median fluorecence intensity (MFI) was derived from each sample 
and the baseline fluorescence, used to identify the Aldefluor positive and negative populations, was 
calculated by the difference between the MFI of sample containing BAAA and the MFI of the same 
sample containing also DEAB. Sorting of the populations of interest was performed on ARIA II cell 
sorter (Beckton Dickinson) to near purity (85%). CD44/CD24 flow cytometric analysis was performed 
with mouse anti-human PE conjugated anti-CD44 and FITC conjugated anti-CD24 antibodies (BD). 
 
Plasmids, transfection, retroviral and lentiviral transfection 
For DNA trasfection Lipofectamine 2000 (Invitrogen) was used and for siRNA trasfection double-
stranded RNA oligos (10pml/cm2) were transfected using Lipofectamine RNAiMax (Invitrogen) 
according to manufacter’s instructions. Retroviruses were made by transient trasfection of 293GP 
packaging cells with the appropriate plasmids with pMD2-ENV coding for envelope proteins, using 
standard calcium-phosphate metod. After 48h incubation at 32°C, the supernatants containing viral 
particles were collacted and infection was performed as described (Rustighi et al., 2009) pCDNA3-N1-
ICD-myc, pCDNA3-N1-ICD-deltaPEST(d2444)-myc, pCDNA3-N1-ICD-T2512A-myc, were generated 
by PCR and standard cloning procedures starting from pCDNA3-NdeltaE-myc (Rustighi et al., 2009) 
constructs as templates. pCDNA3-HA-Pin1 and pCDNA3-HA-S67E, retroviral pLPC-HA-Pin1, 
pCDNA3-HA-Pin1r, were already described (Rustighi et al., 200; Girardini et al., 2011). Retroviral 
pMSCV-3X-Flag-Fbxw7α was obtained by PCR and subcloning from p3X-Flag-Fbxw7α coding for the 
human alpha isoform. pCDNA4-N4-ICD-HA was a kind gift of I. Prudovsky and was already described 
(MacKenzie et al., 2004). For lentiviral infection an shPin1 corrsponding to the siRNA sequence Pin1#1 
was cloned into the Doxicyclin-inducible pLKO-Tet-ON (Addgene) following the “All-in-one” system 
described by D.Wiederschain (dmitri.wiederschain@novartis.com). For preparation of viral particles 
psPAX2 and pMD2.G were used in HEK 293T cells. 
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Oligonucleotides for cloning and mutagenesis: 
 
























To obtain mammospheres, cells from monolayer cultures were enzymatically disaggregated (0.05% 
trypsin–EDTA, Gibco) to a single cell suspension, passed though a 40 lm cell strainer (BD Falcon), 
plated at clonogenic density (2500 cells/cm2), and grown in nonadherent culture conditions, as described 
(Dontu et al, 2003). In detail, cells were grown for 7–10 days in DMEM:F12 (1:1) supplemented with 
B27 (Invitrogen Corporation, Carlsbad, CA, USA), 20 ng/ml EGF (PROSPEC, East Brunswick, NJ, 
USA), 20 ng/ml bFGF (BD Biosciences, San Jose, CA, USA), 4 µg/ml heparin (StemCell Technologies 
Inc.), 0.5 µg/ml hydrocortisone (Sigma) and 5 µg/ml Insulin (Sigma) in low attachment 24 or 96 well 
plates (Coroning) in a humified incubator at 37°C, 5% CO2. Primary mammospheres (≥200 µm) were 
obtained, collected, counted and again enzymatically disaggregated as above to re-plate cells at 
clonogenic densities to obtain secondary mammospheres. The same procedure was applied starting from 
secondary mammospheres to proceed to tertiary and quaternary mammospheres. Percentages of 
mammosphere forming efficiencies (%MFE) were calculated as number of mammospheres divided by 
the plated cell number and multiplied by a hundred. Mammospheres were counted with a 20× objective 
on an Olympus CK30 microscope (Olympus Italia Srl, Milan, Italy).  
 
Quantitative Real Time PCR (qRT–PCR) analysis  
Total RNA from cell lines and xenografts was extracted with QIAzol Lysis Reagent (Qiagen Srl-Italy, 
Milan, Italy). Total RNA from formalin-fixed, paraffin-embedded samples of breast cancer patients was 
extracted starting from 2 to 3 20 lm slices with the HighPure RNA paraffin Kit (Roche SpA, Monza, 
siRNA Sequence 5’-3’ Ref 
siFbxw7α ACCTTCTCTGGAGAGAGAAATGC Welcker et al., 2004 
siPin1 #1 CGGGAGAGGAGGACUUUGA Girardini et al., 2011 
siPin1 #2 GCCAUUUGAAGACGCCUCG Girardini et al., 2011 
siNotch1 GUGUCUGAGGCCAGCAAGA  
siCtrl Allstar NEGATIVE control, Qiagen  
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Italy) and cDNA was transcribed with QuantiTect (Qiagen) in accordance with the manufacturer’s 
protocols, then amplified on a StepOne Plus cycler (Applied Biosystems, Life Technologies Europe BV, 
Monza, Italy), using SYBR Green Universal PCR Master Mix (Applied Biosystems). Histone H3 and 
GAPDH mRNA were used as internal controls. 
 
Oligonucleotides for quantitative real-time PCR: 























Antibodies for Western blot, Far Western, Immunoprecipitations, and Immunohistochemistry. 
The following antibodies were used: rabbit and goat polyclonal anti-Notch1 (C-20: sc-6014, and S-20: sc-
23304, SantaCruz), rabbit polyclonal anti-N1-ICD Val1744 (#2421, Cell Signalling), rabbit polyclonal 
anti-N4-ICD Val1432 (SAB4502023, Sigma), rabbit polyclonal anti-Notch4 (H-225, sc-5594), rabbit 
polyclonal anti-Pin1 (Rustighi et al., 2009) and mouse monoclonal anti-Pin1 (G-8: sc-46660, Santa Cruz), 
rabbit polyclonal anti-HES-1 (#AB5702, Millipore), rabbit polyclonal anti-Slug (#9585S, Cell Signaling), 
mouse monoclonal anti-Vimentin (ab8069, Abcam), mouse monoclonal anti-E-cadherin (610182, BD), 
rabbit monoclonal anti-cleaved Caspase-3 (5A1E, Cell Signaling), rabbit polyclonal anti-Mcl-1 (S-19: sc-
Gene symbol Forward 5’-3’ Reverse 5’-3’ Ref 
Mouse Pin1 GTCTCAGGGATGGGGCTTTT TGGTGGGGCTCAGAGGTATT  
Mouse SMA TGATCACCATTGGAAACGAACG TGGTTTCGTGGATGCCCGCT Stingl et al., 2006 
Mouse CK14 TGAGAGCCTCAAGGAGGAGC TCTCCACATTGACGTCTCCAC Stingl et al., 2006 
Mouse CK18 CTTGCTGGAGGATGGAGAAG CTGCCATCCACGATCTTACGG Stingl et al., 2006 
Mouse CK19 CAGGCTGGAGCAGGAGATCG TGGTAGCTCAGATGGCCTTGG Stingl et al., 2006 
Mouse GAPDH TTCACCACCATGGAGAAGGC CCCTTTTGGCTCCACCCT Li et al., 2009 
Human HES1 GAGAAAAGACGAAGAGCA TGTGCTCAGCGCAGCCGT  
Human HEYL TCCCCACTGCCTTTGAG GGCACTCTTCCCAGGAT Leong et al., 2007 
Human BIRC5 GCCCAGTGTTTCTTCTGCTT CCGGACGAATGCTTTTTATG Cheung et al., 2009 
Human CTGF GTCCGCGTCGCCTTCGTGGTC GAGCACCATCTTTGGCGGTGCAC  
Human SLUG AGATGCATATTCGGACCCAC CCTCATGTTTGTGCAGGAGA Leong et al., 2007 
Human ABCG2 TTTCCAAGCGTTCATTCAAAAA TACGACTGTGACAATGATCTGAGC  
Human GLI1 CCCCAGGGGCTGAGTCCTCC TCCAGAGCTGCCCCGCTGAT  
Human PTCH CTGAGCAACACTCTGATGAA CAGTTAATGACTCCCAAGCA  
Human BMI-1 GTCCAAGTTCACAAGACCAGACC ACAGTCATTGCTGCTGGGCATCG Liu et al., 2006 
Human VIM-1 GAGAACTTTGCCGTTGAAGC GCTTCCTGTAGGTGGCAATC Casas et al., 2011 
Human HMGA2 AGCAGAAGCCACTGGAGAAA TCTTCGGCAGACTCTTGTGA  
Human KLF4 ATTACGCGGGCTGCGGCAAAA TTTTTGGCACTGGAACGGGCGG  
Human DKK GGGAATTACTGCAAAAATGGAATA ATGACCGGAGACAAACAGAAC Butler., 2010 
Human CDH1 TGCCCAGAAAATGAAAAAGG GTGTATGTGGCAATGCGTTC Casas et al., 2011 
Human Pin1 CTGGAGCTGATCAACGGCTACATCC GCAGCGCAAACGAGGCGTCT  
Human Fbxw7 GTGGACCTGCCCGTTCACCAACTCT CGGACCTCAGAACCATGGTCCAACT  
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819, Santa Cruz), for immunoprecipitation and Western blot of endogenous Fbxw7α mouse monoclonal 
(Abnova MO2, 3D1) and rabbit polyclonal (Abcam ab12292) antibodies were used, respectively. For 
tagged proteins rabbit polyclonal and mouse monoclonal (9B11) anti-myc (#2272 and #2276 respectively, 
Cell Signaling), mouse monoclonal anti-Flag clone M2 (F3165, Sigma), anti-GFP rabbit polyclonal 
serum was raised against GST-GFP fusion protein expressed in bacteria, affinity purified and used 
1:1000, mouse monoclonal (12CA5) and rabbit polyclonal (Y-11, sc-805 Santa Cruz) anti-HA. For 
immunohistochemical stainings anti-cleaved Notch1 (Abcam 8925) anti-Notch1 (Santa-Cruz C-20), anti-
Notch4 (Santa Cruz H-225), anti-Fbxw7α (Abnova MO2, 3D1), and anti-Pin1 home made anti-rabbit 
(Rustighi et al. 2009) were used. 
 
Western blot, in vitro binding, immunoprecipitation.  
In vitro binding assays, immuno- and co-immunoprecipitations and Western blot analyses were 
performed by standard procedures, as described (Rustighi et al., 2009). Briefly, for GST and GST-Pin1 
pull-down analysis using cells were lysed in GST pull-down buffer (150 mM NaCl, 50 mM Tris/HCl pH 
7.5, 10% glycerol, 0.1% Nonidet P-40, Sigma), supplemented with inhibitors of phosphatase (1mM 
sodium orthovanadate, 5mM NaF, Sigma) and protease (phenylmethylsulfonylfluoride (PMSF) 1mM and 
chymostatin, leupeptin, antipain, pepstatin 10 µg ml-1 each, Sigma). For Notch1 immunoprecipitations 
cells were treated in all cases with proteasome inhibitor lactacystin for 8 hrs and collected in GST pull-
down buffer as above. Cell lysates were cleared with proteinA Sepharose by rocking for 30 min, then 
Protein A/G sepharose (GE Healthcare) cross-linked antibodies, precleared with 10 mg/ml BSA (Sigma), 
were added. Binding reactions were left for a minimum of 4 hours to over night rocking at 4°C. Then 
beads were washed and bound proteins were loaded and separated in SDS-PAGE, followed by Western 
blotting on Nitrocellulose membranes (Scleicher & Schuell). For β-mercaptoethanol stripping of the 
primary antibody membranes were shortly boiled in 0.1 mM β-mercaptoethanol, 1% SDS, 50 mM 
Tris/HCl pH 6.9, then washed by shaking at RT with PBS, followed by blocking in Blotto-tween (PBS, 
0.2% Tween-20, not fat dry milk 5%) or with TBST (Tris/HCl 25 mM pH7.5) plus 5% BSA (Sigma) 
depending on the antibody. 
Purified GST-Pin1 protein for Far Western analysis was obtained by immobilization, after production in 
bacteria, on glutathione sepharose 4B beads (GEhealthcare) followed by elutions using reduced GSH as a 




Mammary tissue from Pin1+/+ and Pin1-/- mice was collected, formalin fixed and embedded in paraffin. 3 
µm sections were stained with anti-Notch1 (Santa Cruz C-20, 1:50), anti-Notch4 (Santa Cruz H-225, 
1:100), anti-Fbxw7α (Abnova MO2, 3D1, 1:250), and anti-Pin1 (home made anti-rabbit, 1:200, Rustighi 
et al. 2009) antibodies. For immunohistochemical analysis of human breast cancers, anti-cleaved Notch1 
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(Abcam 8925, 1:200), anti-Pin1 (Santa Cruz mouse monoclonal G-8: sc-46660) and the abovementioned 
anti-Fbxw7α antibody were used. Briefly, stainings were performed according to standard procedures for 
paraffin embedded tissue. Slides were deparaffinized, rehydrated and antigen retrieved in a calibrated 
steam pressure cooker with citrate buffer (pH 6.0). Endogenous peroxidase was blocked with peroxidase 
block from an EnVision™ Kit (DakoCytomation, Glostrup, Denmark) for 15 minutes. The slides were 
blocked in 5% nonfat dry milk or PBS + 5% BSA for 20 minutes to 1 hour at room temperature to 
minimize nonspecific binding due to hydrophobic interaction. The slides were then incubated in blocking 
buffer without any antibody (negative control) or with the indicated primary antibodies for 1 hour at 37°C 
or overnight at 4°C. After washing, slides were incubated with secondary universal antibody (Vectastain) 
for 45 minutes at room temperature. Colorimetric detection was completed with diaminobenzidine and 
hydrogen peroxidase for 6 minutes and counterstained with hematoxylin (Sigma-Aldrich, St. Louis, MO, 
USA). The immunostaining was scored semiquantitatively. In the evaluation of activated/cleaved Notch1 
and Fbxw7α only nuclear staining was considered. The scores for IHC were: 0, no staining; 1, few 
nuclear staining of tumor cells (<5% of positive tumor cells); 2, 5-10% of positive tumor cells; 3, >10% 
positive tumor cells. For pairwise comparisons, the scores were collapsed to low (score, 1–2) versus high 
(score, 3) expression, excluding not interpretable samples. 
 
Data acquisition, Image processing, Equipment and settings. 
Western blot films were scanned with an Epson Stylus DX7450 scanner at a grey scale 600 d.p.i. 
resolution and saved as Tiff files. Single panels were cropped to obtain individual layers by Photpshop 
software. Densitometric values of protein levels in Western blot analyses were obtained by Image J 
software. Where necessary, for the sake of clarity, parts of the same or different gels with equal molecular 
weights were cropped and juxtaposed, demarcated with borders and indicated in the figure legend. Images 
of mouse and human immunohistochemical analyses were obtained using Leica DM4000B Microscope 
with DFC420C photocamera. Pictures of Lymph node metastases were taken with an Olympus Super 
bright Zoom Lens F1.8, C-4040200M, 4.1 Megapixel, 7.5 digital zoom. Images of haematoxylin and 
eosin stained sections of pulmonary metastases were obtained with an Olympus BX40 microscope and 
Leica DFC295 CH-9435 camera and were used for Computer-aided assessment of percentage of lung 
tissue area occupied by metastases. Microscope image files were obtained through Leica Application 
Suite LAS 4.1 software.  
 
Breast cancer data collection and processing 
We collected 21 datasets comprising microarray data of breast cancer samples and annotations on 
patients’ clinical outcome. All data were measured on Affymetrix arrays and have been downloaded from 
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) and ArrayExpress 
(http://www.ebi.ac.uk/arrayexpress/). The complete list of datasets is provided in Table S1. Prior to 
analysis, we reorganized the datasets eliminating duplicate samples and samples without outcome 
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information and renamed any original study after the medical center where patients were recruited. 
Briefly, the original studies have been modified as follows:  
-Stockholm has been used as it is and re-named as KI_Stockholm (Karolinska Institutet Stockholm);  -
EMC-286 and EMC-58 have been merged into EMC-344 (Erasmus Medical Center);  -MSK has been 
used as is and re-named as MSKCC (Memorial Sloan-Kettering Cancer Center); -Uppsala-Miller, 
Ivshina-Miller, and Loi datasets (GSE3494, GSE4922, and GSE6532) included samples derived from 
Uppsala University Hospital, John Radcliffe Hospital in Oxford, and Guys Hospital in London. 
Moreover, a comparison of the hybridization dates on the raw files and of the patients’ clinical 
information revealed that, although deposited twice, GSE3494 and GSE4922 were identical. As such, the 
3 series have been split into KI_Uppsala, comprising all 253 unique patients of the Uppsala University 
Hospital, OXF composed of the 178 samples collected at the John Radcliffe Hospital in Oxford, and 
GUY composed of the 87 samples from the Guys Hospital in London; 
-Sotiriou is entirely included in GSE6532; 
-Desmedt has been used as is and renamed as TRANSBIG (after the consortium of cancer centers where 
samples have been collected); 
-Schmidt has been used as is and re-named as Mainz (Johannes Gutenberg University in Mainz); 
-Veridex has been used as is and re-named as Veridex_MultiCenter (after the three European and one US 
institutions where samples have been collected); 
-Tamoxifen has been added to GUY; 
-Chin and Zhou have been merged into UCSF (University of California, San Francisco) after removing 
samples deposited in both GEO (GSE7378) and ArrayExpress (E-TABM-158); 
-TOP TRIAL has been re-named as IJB_TOP (Institut Jules Bordet /Trial of Principle) after removal of 
13 samples lacking of outcome information; 
-GSE19615 has been used as is and re-named as US_NCI (US National Cancer Institute); 
-IPC has been re-named as CRCM (Centre de cancérologie de Marseille) after removal of 14 samples 
lacking of outcome information; 
-KFSYSCC has been used as is and re-named as KOOF (Koo Foundation SYS Cancer Center); 
-GSE31519 has been used as is and re-named as Goethe (Goethe-University, Frankfurt) after removal of 
2 samples lacking of outcome information; 
-Hatzis included samples derived from 4 cohorts, i.e., I-SPY-1 (Investigation of Serial Studies to Predict 
Your Therapeutic Response With Imaging and Molecular Analysis), LBJ_INEN_GEICAM (Lyndon B. 
Johnson Hospital, Instituto Nacional de Enfermedades Neoplásicas, and Grupo Español de Investigación 
en Cáncer de Mama), USO-02103 (US Oncology), and MDACC (M. D. Anderson Cancer Center, 
Houston). The orginal data has been split into I-SPY-1 comprising 83 samples, LBJ_INEN_GEICAM 
comprising 58 samples, MDACC comprising 313 samples, and USO-02103 comprising 54 samples. 
This re-organization resulted in a meta-dataset comprising 3254 unique samples from 19 independent 
cohorts (Table S1). According to Cordenonsi et al. (2011), we standardized clinical information among 
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the various datasets redefining the outcome descriptions based on the clinical annotations of each 
individual study. Specifically, we defined survival as death because of cancer and includes overall 
survival, disease free survival, and disease specific survival. Raw expression data (i.e., CEL files) 
obtained from different platforms have been integrated using an approach inspired by geometry and probe 
content of HG-U133 Affymetrix arrays (Fallarino et al., 2010). Briefly, probes with the same 
oligonucleotide sequence, but located at different coordinates on different type of arrays, may be arranged 
in a virtual platform grid. As for any other microarray geometry, this virtual grid may be used as a 
reference to create a virtual Chip Definition File (virtual-CDF), containing the probes shared among the 
various HG-U133 platforms and their coordinates on the virtual platform, and a virtual-CEL files 
containing the fluorescence intensities of the original CEL files properly re-mapped on the virtual grid. 
Once defined the virtual platform through the creation of the virtual-CDF and transformed the CEL files 
into virtual-CELs, raw data, originally obtained from different HG-U133 arrays, are homogeneous in 
terms of platform and can be preprocessed and normalized adopting standard approaches, as RMA 
(Irizarry et al., 2003). Specifically, expression values were generated from intensity signals using the 
virtual-CDF, obtained merging HG-U133A, HG-U133AAofAV2, and HG-U133 Plus2 original CDFs, 
and the transformed virtual-CEL files. Intensity values for a total of 21981 meta-probe sets have been 
background adjusted, normalized using quantile normalization, and gene expression levels calculated 
using median polish summarization (RMA). The entire procedure has been implemented as an R script. 
To identify two groups of tumor samples with either high or low levels of the Notch-dependent Direct 
Target (NDT) gene signature we used the classifier described in Adorno et al (2009). Briefly, we defined 
a classification rule based on summarizing the standardized expression levels of each gene in NDT 
signature into a combined score with zero mean. Tumors were then classified as NDT signature Low if 
the combined score was negative and as NDT signature High if the combined score was positive. 
Similarly, we defined tumors as expressing high or low levels of Fbxw7 and Pin1 mRNA if the 
standardized expression signal of Fbxw7 and Pin1 probes was positive or negative, respectively. This 




To evaluate the prognostic value of the NDT signatures, we estimated, using the Kaplan-Meier method 
(Kalbfleisch and Prentice), the probabilities that patients would remain free of death (survival). To 
confirm these findings, the Kaplan-Meier curves were compared using the log-rank or Mantel-Haenszel 
test (Harrington and Fleming). P-values were calculated according to the standard normal asymptotic 
distribution. When comparing “NDT signature High” and “NDT signature Low” groups, the group with 
low NDT levels displayed a significantly higher probability (at a significance level α=5x10-2) of a 
reduced survival (Figure S8B). Survival analysis and Kaplan-Meier plots were obtained using R 
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survcomp package. Kaplan-Meyer curves have been compared using the log-rank test of the surv_test 
\function (coin R package). 
Breast cancer re-organized cohorts comprised in the meta-dataset analyzed in this study. 
 
Cohort Affymetrix platform Samples Data source References 
KI_Stockholm HG-U133 A 159 GSE1456 Pawitan et al., 2005 
EMC-344 HG-U133A 344 GSE2034; GSE5327 Wang et al., 2005; Minn et al., 2007 
MSKCC HG-U133A 82 GSE2603 Minn et al., 2005 
KI_Uppsala HG-U133A 253 GSE3494; GSE4922; GSE6532 
Loi et al, 2008; 
Ivshina et al, 2006; 
Miller et al, 2005 
OXF HG-U133A 178 GSE6532 Ivshina et al., 2006 
TransBIG HG-U133A 198 GSE7390 Desmedt et al., 2007 
Mainz HG-U133A 200 GSE11121 Schmidt et al., 2008 
Veridex_MultiCente
r HG-U133A 136 GSE12093 Zhang et al., 2009 
GUY HG-U133 Plus 2.0 164 GSE6532; GSE9195 
Loi et al., 2007; Loi 
et al., 2008; Loi et 
al., 2010 
UCSF HG-U133AAofAV2 166 E-TABM-158; GSE7378 
Merritt et al., 2008; 
Zhou T et al., 2007; 
Yau C et al., 2008 
IJB_TOP HG-U133 Plus 2.0 107  GSE16446 
Desmedt Cet al., 
2011; Li Y et al., 
2010; Juul N et al., 
2010 
US_NCI HG-U133 Plus 2.0 115 GSE19615 Li Y t al., 2010 
CRCM HG-U133 Plus 2.0 252 GSE21653 Sabatier R et al., 2011 
KOOF HG-U133 Plus 2.0 327 GSE20685 Kao KJ et al., 2011 
Goethe HG-U133A 65 GSE31519 
Rody A. et al., 2011; 
Karn T. et al., 2011; 
Karn T. et al., 2012 
MDACC HG-U133A 313 GSE25066 Hatzis C. et al., 2012 
I-SPY-1 HG-U133A 83  GSE25066 Hatzis C. et al., 2012 
LBJ_INEN_GEICA
M HG-U133A 58  GSE25066 Hatzis C. et al., 2012 
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Gene name ENTREZ ID Reference 
HES1 3280 Grabher et al., 2006 
HEY1 23462 Grabher et al., 2006 
HEY2 23493 Grabher et al., 2006 
HEYL 26508 Grabher et al., 2006 
MYC 4609 Palomero et al., 2006; Weng et al., 2006 
BUB1B 701 Palomero et al., 2006 
BUB3 9184 Palomero et al., 2006 
CDC25A 993 Palomero et al., 2006 
PHB 5245 Palomero et al., 2006 
RBL1 5933 Palomero et al., 2006 
RPL3 6122 Palomero et al., 2006 
USP5 8078 Palomero et al., 2006 
PLAU 5328 Shimizu et al., 2011 
SHQ 55164 Chadwick et al., 2009 
CCND1 595 Ronchini and Capobianco, 2001 
GATA3 2625 Amsen et al., 2007 
SKP2 6502 Sarmento et al., 2005  
ERBB2 2064 Chen et al., 1997 
CDKN1A 1026 Rangarajan et al., 2001 
SNAI1 6615 Sahlgren et al., 2008 
SNAI2 6591 Leong et al., 2007 
NFKB2 4791 Oswald et al., 1998 
BIRC5 332 Lee et al., 2008 
NOTCH1 4851 Weng et al., 2006; Hamidi et al., 2011 
NOTCH3 4854 Weng et al., 2006; Hamidi et al., 2011 
NOTCH4 4855 Hamidi et al., 2011 
IFRD2 7866 Palomero et al., 2006 
ING3 54556 Palomero et al., 2006 
PTCRA 171558 Grabher et al., 2006 
CD3D 915 Palomero et al., 2006 
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